

Liang Cheng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/502162/publications.pdf>

Version: 2024-02-01

1,041
papers

40,819
citations

2423

97
h-index

10127

140
g-index

1113
all docs

1113
docs citations

1113
times ranked

28267
citing authors

#	ARTICLE	IF	CITATIONS
1	Improvement of uniformity of biocemented sand column using CH ₃ COOH-buffered one-phase-low-pH injection method. <i>Acta Geotechnica</i> , 2023, 18, 413-428.	2.9	7
2	Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management. <i>Human Pathology</i> , 2023, 133, 56-75.	1.1	12
3	International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma. <i>European Urology Focus</i> , 2022, 8, 438-446.	1.6	20
4	Reply to Rodolfo Montironi, Marina Scarpelli, Alessia Cimadamore, and Gregor Mikuz's Letter to the Editor re: Theo van der Kwast, Fredrik Liedberg, Peter C. Black, et al. International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma. <i>Eur Urol Focus</i> . In press. https://doi.org/10.1016/j.euf.2021.03.017 . Focus on Our Personal Recollections and Observations. <i>European Urology Focus</i> , 2022, 8, 885-886.	1.6	1
5	Low-grade oncocytic tumour expands the spectrum of renal oncocytic tumours and deserves separate classification: a review of 23 cases from a single tertiary institute. <i>Journal of Clinical Pathology</i> , 2022, 75, 772-775.	1.0	26
6	Bio-mediated soil improvement: An introspection into processes, materials, characterization and applications. <i>Soil Use and Management</i> , 2022, 38, 68-93.	2.6	43
7	Somatic-Type Yolk Sac Tumor Arising as a Predominant Component of Bladder Urothelial Carcinoma. <i>International Journal of Surgical Pathology</i> , 2022, 30, 207-213.	0.4	3
8	A genome-wide cross-trait analysis highlights the shared genetic structure between COVID-19 and Alzheimer's disease. <i>Journal of Infection</i> , 2022, 84, e1-e2.	1.7	9
9	gutMGene: a comprehensive database for target genes of gut microbes and microbial metabolites. <i>Nucleic Acids Research</i> , 2022, 50, D795-D800.	6.5	67
10	Sustained and enhanced anaerobic removal of COD and nitrogen in a zeolite amended glycogen accumulating organism dominated biofilm process. <i>Science of the Total Environment</i> , 2022, 807, 150602.	3.9	9
11	A comprehensive review of the analysis and integration of omics data for SARS-CoV-2 and COVID-19. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	9
12	SCovid: single-cell atlases for exposing molecular characteristics of COVID-19 across 10 human tissues. <i>Nucleic Acids Research</i> , 2022, 50, D867-D874.	6.5	28
13	Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metastatic sites. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 1261-1268.	1.4	12
14	High-intensity focused ultrasound for the treatment of prostate cancer: assessing location of failure after focal therapy in prostate cancer and review of histological characteristics and clinicopathologic correlates after treatment—a 5-year experience. <i>Human Pathology</i> , 2022, 119, 79-84.	1.1	3
15	Spectrum of incipient (or precursor) lesions in the mucosa of the seminal vesicles. <i>Pathology Research and Practice</i> , 2022, 229, 153737.	1.0	0
16	<i>BIN1</i> rs744373 located in enhancers of brain tissues upregulates <i>BIN1</i> mRNA expression, thereby leading to Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 1587-1588.	0.4	8
17	Construction of Water Pond Using Bioslurry-Induced Biocementation. <i>Journal of Materials in Civil Engineering</i> , 2022, 34, .	1.3	13
18	Efficient persistent organic pollutant removal in water using MIL-metal-organic framework driven Fenton-like reactions: A critical review. <i>Chemical Engineering Journal</i> , 2022, 431, 134182.	6.6	46

#	ARTICLE	IF	CITATIONS
19	Targeting Protein Arginine Methyltransferase 5 Suppresses Radiation-induced Neuroendocrine Differentiation and Sensitizes Prostate Cancer Cells to Radiation. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 448-459.	1.9	13
20	Does pathological sub stratification of T2 bladder cancer predict outcome in a contemporary pure urothelial carcinoma cohort?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 196.e11-196.e16.	0.8	1
21	T1 bladder carcinoma with variant histology: pathological features and clinical significance. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 989-998.	1.4	15
22	Recurrent KRAS mutations are early events in the development of papillary renal neoplasm with reverse polarity. <i>Modern Pathology</i> , 2022, 35, 1279-1286.	2.9	17
23	Highly dispersed and stable nano zero-valent iron doped electrospun carbon nanofiber composite for aqueous hexavalent chromium removal. <i>RSC Advances</i> , 2022, 12, 8178-8187.	1.7	5
24	Recent Advances of Deep Learning for Computational Histopathology: Principles and Applications. <i>Cancers</i> , 2022, 14, 1199.	1.7	37
25	Granulomas associated with renal neoplasms: A multi-institutional clinicopathological study of 111 cases. <i>Histopathology</i> , 2022, , .	1.6	1
26	Identification of Nine mRNA Signatures for Sepsis Using Random Forest. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-7.	0.7	2
27	ELECTRA-DTA: a new compound-protein binding affinity prediction model based on the contextualized sequence encoding. <i>Journal of Cheminformatics</i> , 2022, 14, 14.	2.8	11
28	Pan-cancer analysis reveals sex-specific signatures in the tumor microenvironment. <i>Molecular Oncology</i> , 2022, 16, 2153-2173.	2.1	13
29	Preparation and Characterization of Multi-Doped Porous Carbon Nanofibers from Carbonization in Different Atmospheres and Their Oxygen Electrocatalytic Properties Research. <i>Nanomaterials</i> , 2022, 12, 832.	1.9	7
30	The pathological and molecular genetic landscape of the hereditary renal cancer predisposition syndromes. <i>Histopathology</i> , 2022, 81, 15-31.	1.6	2
31	Coupling effect of biocementation-fiber reinforcement on mechanical behavior of calcareous sand for ocean engineering. <i>Bulletin of Engineering Geology and the Environment</i> , 2022, 81, 1.	1.6	14
32	Mechanical Behavior and Microstructural Study of Biocemented Sand under Various Treatment Methods. <i>Geofluids</i> , 2022, 2022, 1-11.	0.3	2
33	Current androgen receptor antagonists under investigation for resistant prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 191-202.	1.1	5
34	Artificial intelligence in prostate cancer: Definitions, current research, and future directions. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 262-270.	0.8	4
35	Enhancing splitting tensile strength of biocarbonated reactive magnesia-based sand using polypropylene fiber reinforcement. <i>Acta Geotechnica</i> , 2022, 17, 4761-4768.	2.9	1
36	Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance. <i>Npj Precision Oncology</i> , 2022, 6, 31.	2.3	37

#	ARTICLE	IF	CITATIONS
37	Impact of biosurfactant and iron nanoparticles on biodegradation of polyaromatic hydrocarbons (PAHs). <i>Environmental Pollution</i> , 2022, 306, 119384.	3.7	28
38	Removal of Chromium(VI) by Nanoscale Zero-Valent Iron Supported on Melamine Carbon Foam. <i>Nanomaterials</i> , 2022, 12, 1866.	1.9	4
39	Atypical cartilage in type II germ cell tumors of the mediastinum show significantly different patterns of IDH1/2 mutations from conventional chondrosarcoma. <i>Modern Pathology</i> , 2022, 35, 1636-1643.	2.9	1
40	Boosting the singlet oxygen production from H ₂ O ₂ activation with highly dispersed Co ^{II} -N-graphene for pollutant removal. <i>RSC Advances</i> , 2022, 12, 17864-17872.	1.7	8
41	Clinicopathologic and Immunohistochemical Characterization of Sarcomatoid Chromophobe Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2022, 46, 1171-1179.	2.1	4
42	Morphologic spectrum of treatment-related changes in prostate tissue and prostate cancer: an updated review. <i>Human Pathology</i> , 2022, 127, 56-66.	1.1	4
43	Mixed epithelial and stromal tumours of the kidney with malignant transformation: a clinicopathological study of four cases. <i>Pathology</i> , 2022, , .	0.3	0
44	Deep-DRM: a computational method for identifying disease-related metabolites based on graph deep learning approaches. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	55
45	Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives. <i>European Urology Focus</i> , 2021, 7, 955-963.	1.6	13
46	Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. <i>Gut</i> , 2021, 70, 148-156.	6.1	139
47	Chromophobe Renal Cell Carcinoma Aggressiveness and Immuno-oncology Therapy: How to Distinguish the Good One from the Bad One. <i>European Urology Oncology</i> , 2021, 4, 331-333.	2.6	5
48	Role of Neoadjuvant Chemotherapy in Squamous Variant Histology in Urothelial Bladder Cancer: Does Presence and Percentage Matter?. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 47-52.	0.9	6
49	Re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti-PD-1/PD-L1 in Advanced Urothelial Cancer. <i>Eur Urol</i> 2020;77:269-76. <i>European Urology</i> , 2021, 79, e17-e19.	0.9	1
50	Grading of Chromophobe Renal Cell Carcinoma: Do We Need It?. <i>European Urology</i> , 2021, 79, 232-233.	0.9	7
51	Exciting experiences in the "Rocky road to digital diagnostics". <i>Journal of Clinical Pathology</i> , 2021, 74, 5-6.	1.0	4
52	Herbicidal activity of <i>Beauveria</i> sp. from Tibetan Plateau biome against <i>Avena fatua</i> L.. <i>Biocontrol Science and Technology</i> , 2021, 31, 265-283.	0.5	0
53	Clinical Considerations and Prognosis of Well-Differentiated Neuroendocrine Tumor Occurring Within a Renal Teratoma—A Case Series. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e72-e77.	0.9	5
54	Stage T1 bladder cancer: diagnostic criteria and pitfalls. <i>Pathology</i> , 2021, 53, 67-85.	0.3	11

#	ARTICLE	IF	CITATIONS
55	Promising novel therapies for relapsed and refractory testicular germ cell tumors. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 53-69.	1.1	4
56	Prostate cancer grading, time to go back to the future. <i>BJU International</i> , 2021, 127, 165-168.	1.3	4
57	Invasive poorly differentiated adenocarcinoma of the bladder following augmentation cystoplasty: a multi-institutional clinicopathological study. <i>Pathology</i> , 2021, 53, 214-219.	0.3	4
58	Biocarbonation of reactive magnesia for soil improvement. <i>Acta Geotechnica</i> , 2021, 16, 1113-1125.	2.9	27
59	Intraductal carcinoma of the prostate is not a diagnostic entity. <i>Histopathology</i> , 2021, 78, 342-344.	1.6	6
60	Added Clinical Value of Whole-mount Histopathology of Radical Prostatectomy Specimens: A Collaborative Review. <i>European Urology Oncology</i> , 2021, 4, 558-569.	2.6	11
61	Genitourinary Neoplasms. , 2021, , 233-244.		0
62	Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer. <i>Cancers</i> , 2021, 13, 131.	1.7	153
63	Predicting future cancer burden in the United States by artificial neural networks. <i>Future Oncology</i> , 2021, 17, 159-168.	1.1	8
64	A comprehensive review for gut microbes: technologies, interventions, metabolites and diseases. <i>Briefings in Functional Genomics</i> , 2021, 20, 42-60.	1.3	19
65	Distal Tubular Hyperplasia. <i>American Journal of Surgical Pathology</i> , 2021, 45, 516-522.	2.1	3
66	Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. <i>Modern Pathology</i> , 2021, 34, 1167-1184.	2.9	118
67	Room-Temperature Hydrogen-Sensing Capabilities of Pt-SnO ₂ and Pt-ZnO Composite Nanoceramics Occur via Two Different Mechanisms. <i>Nanomaterials</i> , 2021, 11, 504.	1.9	6
68	Multitarget fluorescence in situ hybridization diagnostic applications in solid and hematological tumors. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 161-173.	1.5	2
69	An update on investigational therapies that target STAT3 for the treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 245-251.	1.9	13
70	Mixed germ cell-sex cord stromal tumour of the testis and ovary: comparison and contrast. <i>Pathology</i> , 2021, 53, 166-169.	0.3	1
71	Functional alterations caused by mutations reflect evolutionary trends of SARS-CoV-2. <i>Briefings in Bioinformatics</i> , 2021, 22, 1442-1450.	3.2	32
72	Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF?. <i>Translational Andrology and Urology</i> , 2021, 10, 1581-1587.	0.6	3

#	ARTICLE	IF	CITATIONS
73	Towards a new WHO classification of renal cell tumor: what the clinician needs to know—a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 1506-1520.	0.6	34
74	Synthesis, crystal growth, characterization and DFT investigation of a nonlinear optically active cuminaldehyde derivative hydrazone. <i>Acta Crystallographica Section B: Structural Science, Crystal Engineering and Materials</i> , 2021, 77, 249-259.	0.5	7
75	Immunohistochemical Characterization of 120 Testicular Sex Cord-Stromal Tumors With an Emphasis on the Diagnostic Utility of SOX9, FOXL2, and SF-1. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1303-1313.	2.1	18
76	Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder. <i>Journal of Clinical Pathology</i> , 2021, 74, 491-495.	1.0	18
77	Digital diagnostics and artificial intelligence in prostate cancer treatment in 5 years from now. <i>Translational Andrology and Urology</i> , 2021, 10, 1499-1505.	0.6	6
78	Narrative review: predicting future molecular and clinical profiles of prostate cancer in the United States. <i>Translational Andrology and Urology</i> , 2021, 10, 1562-1568.	0.6	2
79	Telomerase reverse transcriptase (TERT) promoter mutations in primary adenocarcinoma of bladder and urothelial carcinoma with glandular differentiation: pathogenesis and diagnostic implications. <i>Modern Pathology</i> , 2021, 34, 1384-1391.	2.9	9
80	Let us not forget about our past contributions to the field of prostatic neoplasms: To some extent what we value now was already there. <i>Pathology Research and Practice</i> , 2021, 219, 153377.	1.0	0
81	Narrative review: update on immunotherapy and pathological features in patients with bladder cancer. <i>Translational Andrology and Urology</i> , 2021, 10, 1521-1529.	0.6	11
82	New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. <i>Modern Pathology</i> , 2021, 34, 1392-1424.	2.9	138
83	Narrative review of prostate cancer grading systems: will the Gleason scores be replaced by the Grade Groups?. <i>Translational Andrology and Urology</i> , 2021, 10, 1530-1540.	0.6	10
84	TNM staging towards a personalized approach in metastatic urothelial carcinoma: what will the future be like—a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 1541-1552.	0.6	6
85	Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups. <i>European Urology</i> , 2021, 79, 489-491.	0.9	4
86	Transforming Pt-SnO ₂ Nanoparticles into Pt-SnO ₂ Composite Nanoceramics for Room-Temperature Hydrogen-Sensing Applications. <i>Materials</i> , 2021, 14, 2123.	1.3	7
87	Incidental Prostate Cancer (cT1a-cT1b) Is a Relevant Clinical and Research Entity and Should Be Fully Discussed in the International Prostate Cancer Guidelines. <i>European Urology Oncology</i> , 2021, , .	2.6	6
88	The Wide Spectrum of Oncocytic Changes and Tumors in the Kidney: Splitting and Lumping. <i>Pathobiology</i> , 2021, 88, 1-4.	1.9	0
89	Lesson from the COVID-19 pandemic: pathologists need to build their confidence on working in a digital microscopy environment. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 227-229.	1.4	5
90	Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5522.	1.8	12

#	ARTICLE	IF	CITATIONS
91	Noninvasive papillary urothelial neoplasia (NIPUN): Renaming cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 286-290.	0.8	6
92	COVID-19 induces lower levels of IL-8, IL-10, and MCP-1 than other acute CRS-inducing diseases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	16
93	An update on immunotherapy in uro-oncology. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 229-233.	0.4	2
94	Biologically reduced graphene oxide as a green and easily available photocatalyst for degradation of organic dyes. <i>Environmental Research</i> , 2021, 196, 110983.	3.7	51
95	Reply to Alessia Cimadamore, Antonio Lopez-Beltran, Marina Scarpelli, and Rodolfo Montironi's Letter to the Editor re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups. <i>Eur Urol</i> 2021;79:489-91. <i>European Urology</i> , 2021, 79, e174-e175.	0.9	0
96	EWSR1-PATZ1 fusion renal cell carcinoma: a recurrent gene fusion characterizing thyroid-like follicular renal cell carcinoma. <i>Modern Pathology</i> , 2021, 34, 1921-1934.	2.9	28
97	Renal oncocytoma with adverse pathologic features: a clinical and pathologic study of 50 cases. <i>Modern Pathology</i> , 2021, 34, 1947-1954.	2.9	2
98	Genetic and epigenetic regulation in neoplasms composed of both germ cells and sex cord elements. <i>Pathology Research and Practice</i> , 2021, 222, 153428.	1.0	0
99	Clear cell papillary renal cell carcinoma: Characteristics and survival outcomes from a large single institutional series. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 370.e21-370.e25.	0.8	6
100	The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. <i>Advances in Anatomic Pathology</i> , 2021, 28, 196-208.	2.4	20
101	The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia. <i>Advances in Anatomic Pathology</i> , 2021, 28, 179-195.	2.4	23
102	The Coronavirus Disease 2019 (COVID-19) Pandemic's Impact on Social Interaction in Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 1049-1050.	1.2	1
103	Reply to Nicolas Mottet, Olivier Rouviere, and Theodorus H. van der Kwast. Incidental Prostate Cancer: A Real Need for Expansion in Guidelines? <i>Eur Urol Oncol</i> . In press. <i>European Urology Oncology</i> , 2021, 5, 261-261.	2.6	0
104	Highly differentiated follicular thyroid-type carcinoma of the ovary reconsidered. <i>Journal of Clinical Pathology</i> , 2021, 74, 553-557.	1.0	3
105	Briefings in functional genomics special section editorial: analysis of integrated multiple omics data. <i>Briefings in Functional Genomics</i> , 2021, 20, 196-197.	1.3	1
106	Digital whole mount sections of the prostate: heading towards new ways of communicating with clinicians and patients without microscope. <i>Minerva Urology and Nephrology</i> , 2021, , .	1.3	1
107	Prioritizing Disease-Related Microbes Based on the Topological Properties of a Comprehensive Network. <i>Frontiers in Microbiology</i> , 2021, 12, 685549.	1.5	2
108	Identification of Gene Signature Associated with Type 2 Diabetes Mellitus by Integrating Mutation and Expression Data. <i>Current Gene Therapy</i> , 2021, 22, 51-58.	0.9	3

#	ARTICLE	IF	CITATIONS
109	Molecular pathology of urothelial carcinoma. <i>Human Pathology</i> , 2021, 113, 67-83.	1.1	24
110	Prostate Cancer in 2021: Novelty in Prognostic and Therapeutic Biomarker Evaluation. <i>Cancers</i> , 2021, 13, 3471.	1.7	9
111	Non-coding RNAs as Novel Biomarkers in Cancer Drug Resistance. <i>Current Medicinal Chemistry</i> , 2021, 28, .	1.2	10
112	Integration of Multiple-Omics Data to Analyze the Population-Specific Differences for Coronary Artery Disease. <i>Computational and Mathematical Methods in Medicine</i> , 2021, 2021, 1-11.	0.7	40
113	Adsorption of organic compounds from aqueous solution by pyridine-2-carboxaldehyde grafted MIL-101(Cr)-NH ₂ metal-organic frameworks. <i>Journal of Environmental Chemical Engineering</i> , 2021, 9, 105275.	3.3	28
114	Incidentally discovered myelolipomatous adrenal adenomas, including six cases presenting with hypercortisolism. <i>Pathology Research and Practice</i> , 2021, 224, 153508.	1.0	0
115	Colorectal cancer with microsatellite instability: Right-sided location and signet ring cell histology are associated with nodal metastases, and extranodal extension influences disease-free survival. <i>Pathology Research and Practice</i> , 2021, 224, 153519.	1.0	7
116	Experimental and Analytical Study on Geomechanical Behavior of Biocemented Sand. <i>International Journal of Geomechanics</i> , 2021, 21, .	1.3	15
117	Metastatic urothelial carcinoma to the brain, spinal cord and spine: A contemporary multi-institutional clinicopathologic analysis of 24 cases. <i>Pathology Research and Practice</i> , 2021, 224, 153537.	1.0	3
118	Re: Bas W.G. van Rhijn, Anouk E. Hentschel, Johannes Brähler, et al. Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. <i>Eur Urol Oncol</i> 2021;4:182-91. <i>European Urology Oncology</i> , 2021, 4, 671-673.	2.6	1
119	Evaluating mismatch repair deficiency for solid tumor immunotherapy eligibility: immunohistochemistry versus microsatellite molecular testing. <i>Human Pathology</i> , 2021, 115, 10-18.	1.1	11
120	Re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2021.03.009 . <i>European Urology</i> , 2021, 80, e81-e82.	0.9	0
121	Bio-Cementation for Improving Soil Thermal Conductivity. <i>Sustainability</i> , 2021, 13, 10238.	1.6	11
122	<i>Lactiplantibacillus plantarum</i> Reduced Renal Calcium Oxalate Stones by Regulating Arginine Metabolism in Gut Microbiota. <i>Frontiers in Microbiology</i> , 2021, 12, 743097.	1.5	4
123	Adrenal Myelolipoma: 369 Cases From a High-Volume Center. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 663346.	1.1	4
124	Genomic characterization of hepatoid tumors: context matters. <i>Human Pathology</i> , 2021, 118, 30-41.	1.1	9
125	Enhanced biodegradation of hydrophobic organic pollutants by the bacterial consortium: Impact of enzymes and biosurfactants. <i>Environmental Pollution</i> , 2021, 289, 117956.	3.7	60
126	SubtypeDrug: a software package for prioritization of candidate cancer subtype-specific drugs. <i>Bioinformatics</i> , 2021, 37, 2491-2493.	1.8	24

#	ARTICLE	IF	CITATIONS
127	Diagnostic approach in TFE3-rearranged renal cell carcinoma: a multi-institutional international survey. <i>Journal of Clinical Pathology</i> , 2021, 74, 291-299.	1.0	14
128	CNA2Subpathway: identification of dysregulated subpathway driven by copy number alterations in cancer. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	16
129	Fluorescence In Situ Hybridization (FISH) Detection of Chromosomal 12p Anomalies in Testicular Germ Cell Tumors. <i>Methods in Molecular Biology</i> , 2021, 2195, 49-63.	0.4	5
130	Update on Prostate Cancer Diagnosis, Prognosis, and Prediction to Response to Therapy. <i>Cells</i> , 2021, 10, 20.	1.8	4
131	A Simplified Diagnostic Approach on TFE3 Gene Fusion-associated Renal Cell Carcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 132-134.	1.2	1
132	What's the future in uro pathology. <i>Urologia</i> , 2021, 88, 265-266.	0.3	0
133	Editorial: Omics Data Integration Towards Mining of Phenotype Specific Biomarkers in Cancers and Diseases. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 763447.	1.8	1
134	A pyramidal deep learning pipeline for kidney whole-slide histology images classification. <i>Scientific Reports</i> , 2021, 11, 20189.	1.6	5
135	Incorporating Transcriptomic-Metabolomic analysis reveal the effect of ultrasound on ethanol production in <i>Saccharomyces Cerevisiae</i> . <i>Ultrasonics Sonochemistry</i> , 2021, 79, 105791.	3.8	9
136	Molecular Characterization of Testicular Germ Cell Tumors Using Tissue Microdissection. <i>Methods in Molecular Biology</i> , 2021, 2195, 31-47.	0.4	6
137	Molecular Classification of Bladder Urothelial Carcinoma Using NanoString-Based Gene Expression Analysis. <i>Cancers</i> , 2021, 13, 5500.	1.7	16
138	Deep Learning-based Classification of Epithelial-Mesenchymal Transition for Predicting Response to Therapy in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 782515.	1.3	3
139	Carcinosarcoma, a Rare Malignant Neoplasm of the Pancreas. <i>Current Oncology</i> , 2021, 28, 5295-5303.	0.9	3
140	Artificial intelligence and prostate cancer: Advances and challenges. <i>Urologia</i> , 2021, , 039156032110624.	0.3	1
141	Integrative Analysis of Pathological Images and Multi-Dimensional Genomic Data for Early-Stage Cancer Prognosis. <i>IEEE Transactions on Medical Imaging</i> , 2020, 39, 99-110.	5.4	54
142	Liquid biopsies in urological cancers: what we need to know before starting using them. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 135-139.	1.5	5
143	Recurrent KRAS mutations in papillary renal neoplasm with reverse polarity. <i>Modern Pathology</i> , 2020, 33, 1157-1164.	2.9	48
144	Re: Lorenzo Marconi, Thomas Stonier, Rafael Tourinho-Barbosa, et al. Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. <i>Eur Urol</i> 2019;76:27-30. <i>European Urology</i> , 2020, 77, e100-e102.	0.9	0

#	ARTICLE	IF	CITATIONS
145	gutMDisorder: a comprehensive database for dysbiosis of the gut microbiota in disorders and interventions. <i>Nucleic Acids Research</i> , 2020, 48, D554-D560.	6.5	152
146	Prostate cancer pathology: What has changed in the last 5 years. <i>Urologia</i> , 2020, 87, 3-10.	0.3	6
147	An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 207-217.	1.5	5
148	Liquid biopsy in the clinical management of bladder cancer: current status and future developments. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 255-264.	1.5	14
149	Neoplasms of the Prostate. , 2020, , 415-525.e42.		3
150	Renal Pelvis and Ureter. , 2020, , 164-178.e4.		1
151	Neoplasms of the Urinary Bladder. , 2020, , 230-321.e19.		3
152	Practical Molecular Testing in a Clinical Genitourinary Service. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 277-289.	1.2	5
153	Neoplasms of the Kidney. , 2020, , 83-163.e23.		2
154	Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 141-150.	1.5	14
155	Renal cell tumors with an entrapped papillary component: a collision with predilection for oncocytic tumors. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 399-407.	1.4	9
156	Liquid biopsy in germ cell tumors: biology and clinical management. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 187-194.	1.5	10
157	The Utility of ERBB4 and RB1 Immunohistochemistry in Distinguishing Chromophobe Renal Cell Carcinoma From Renal Oncocytoma. <i>International Journal of Surgical Pathology</i> , 2020, 28, 259-264.	0.4	7
158	Five decades of urologic pathology: the accelerating expansion of knowledge in renal cell neoplasia. <i>Human Pathology</i> , 2020, 95, 24-45.	1.1	17
159	Microsatellite instability and mismatch repair deficiency in the era of precision immuno-oncology. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 1-4.	1.1	8
160	Primary Renal Synovial Sarcomas: PAX 8 Immunostaining and Unusual Molecular Findings. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 221-228.	0.6	10
161	Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 262-268.	0.8	15
162	Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 231-243.	1.5	24

#	ARTICLE	IF	CITATIONS
163	Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be graded. <i>Pathology</i> , 2020, 52, 192-196.	0.3	29
164	Fluorescence In Situ Hybridization for the X and Y Chromosome Centromeres Helps Differentiate Between Gestational and Nongestational Choriocarcinoma in Clinically Ambiguous Cases. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 863-868.	1.2	7
165	psSubpathway: a software package for flexible identification of phenotype-specific subpathways in cancer progression. <i>Bioinformatics</i> , 2020, 36, 2303-2305.	1.8	48
166	Gonadoblastoma: origin and outcome. <i>Human Pathology</i> , 2020, 100, 47-53.	1.1	19
167	Micropapillary urothelial carcinoma of urinary bladder displays immunophenotypic features of luminal and p53-like subtypes and is not a variant of adenocarcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 449-458.	0.8	14
168	Insulinoma-associated Protein 1 (INSM1) Expression in Small Cell Neuroendocrine Carcinoma of the Urinary Tract. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 687-693.	0.6	13
169	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. <i>Cancers</i> , 2020, 12, 84.	1.7	22
170	Conjoint Feature Representation of GO and Protein Sequence for PPI Prediction Based on an Inception RNN Attention Network. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 22, 198-208.	2.3	18
171	Morphologic and Immunohistochemical Characteristics of Fluorescent In Situ Hybridization Confirmed TFE3-Gene Fusion Associated Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2020, 44, 1450-1458.	2.1	12
172	Designing novel immunocombinations in metastatic renal cell carcinoma. <i>Immunotherapy</i> , 2020, 12, 1257-1268.	1.0	6
173	Gonadoblastoma versus ovarian mixed germ cell-sex cord stromal tumor in women or girls with no evidence of a disorder of sex development: A problem in differential diagnosis. <i>Pathology Research and Practice</i> , 2020, 216, 153198.	1.0	5
174	MRTFB regulates the expression of NOMO1 in colon. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 7568-7569.	3.3	24
175	Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 755-763.	1.1	14
176	Urothelial carcinoma in situ response to cisplatin-based neoadjuvant chemotherapy, or lack thereof: Impact on patient selection for organ preservation in muscle-invasive disease?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 850.e1-850.e7.	0.8	3
177	The relationship between gut microbiota and short chain fatty acids in the renal calcium oxalate stones disease. <i>FASEB Journal</i> , 2020, 34, 11200-11214.	0.2	51
178	Identification of a Multi-Long Noncoding RNA Signature for the Diagnosis of Type 1 Diabetes Mellitus. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 553.	2.0	11
179	Laparoscopic and Robotic-Assisted Partial Nephrectomy: An Overview of Hot Issues. <i>Urologia Internationalis</i> , 2020, 104, 669-677.	0.6	17
180	Editorial: System Biology Methods and Tools for Integrating Omics Data. <i>Frontiers in Genetics</i> , 2020, 11, 563108.	1.1	0

#	ARTICLE	IF	CITATIONS
181	Restraint of Particle Breakage by Biotreatment Method. Journal of Geotechnical and Geoenvironmental Engineering - ASCE, 2020, 146, .	1.5	109
182	Is There a Role for Immunotherapy in Prostate Cancer?. Cells, 2020, 9, 2051.	1.8	65
183	Digital pathology and COVID-19 and future crises: pathologists can safely diagnose cases from home using a consumer monitor and a mini PC. Journal of Clinical Pathology, 2020, 73, 695-696.	1.0	25
184	Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications. Cells, 2020, 9, 2653.	1.8	98
185	Renal Volume Loss During Partial Nephrectomy Due to Resected Healthy Parenchyma: A Tool for Quick Estimation. Journal of Endourology, 2020, 34, 856-861.	1.1	2
186	High-strength wastewater treatment using microbial biofilm reactor: a critical review. World Journal of Microbiology and Biotechnology, 2020, 36, 75.	1.7	41
187	Urologists During the COVID-19 Pandemic: What Can Be Learned in Terms of Social Interaction, Visibility, and Social Distance. European Urology, 2020, 78, 478-481.	0.9	8
188	Preliminary immunohistochemical expression correlates with prostate cancer aggressiveness. International Journal of Biological Markers, 2020, 35, 82-90.	0.7	2
189	DeepLGP: a novel deep learning method for prioritizing lncRNA target genes. Bioinformatics, 2020, 36, 4466-4472.	1.8	106
190	Report From the International Society of Urological Pathology (ISUP) Consultation Conference On Molecular Pathology Of Urogenital Cancers. II. Molecular Pathology of Bladder Cancer. American Journal of Surgical Pathology, 2020, 44, e30-e46.	2.1	38
191	Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma. Cancers, 2020, 12, 1449.	1.7	72
192	Granular necrosis: a distinctive form of cell death in malignant tumours. Pathology, 2020, 52, 507-514.	0.3	20
193	Reappraisal of the papillary urothelial neoplasm of low malignant potential (PUNLMP). Histopathology, 2020, 77, 525-535.	1.6	10
194	Polymorphonuclear MDSCs are enriched in the stroma and expanded in metastases of prostate cancer. Journal of Pathology: Clinical Research, 2020, 6, 171-177.	1.3	22
195	Re: Multi-institutional Re-evaluation of Prognostic Factors in Chromophobe Renal Cell Carcinoma: Proposal of a Novel Two-tiered Grading Scheme. European Urology, 2020, 78, 114-116.	0.9	4
196	Cystic Trophoblastic Tumor in a Primary Central Nervous System Post-Chemotherapy Germ Cell Tumor: The First Case Report. International Journal of Surgical Pathology, 2020, 28, 925-928.	0.4	1
197	Gene fusion characterisation of rare aggressive prostate cancer variants: adenocarcinoma, pleomorphic giant cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases. Histopathology, 2020, 77, 890-899.	1.6	15
198	Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer. Cells, 2020, 9, 1495.	1.8	8

#	ARTICLE	IF	CITATIONS
199	New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?. <i>Cells</i> , 2020, 9, 1522.	1.8	6
200	Gonadoblastoma in individuals with a normal karyotype and no evidence of a disorder of sex development. <i>Pathology</i> , 2020, 52, 605-607.	0.3	4
201	Predictors of Prostate-specific Membrane Antigen (PSMA/FOLH1) Expression in a Genomic Database. <i>Urology</i> , 2020, 144, 117-122.	0.5	2
202	Immunophenotypic and pathologic heterogeneity of unclassified renal cell carcinoma: a study of 300 cases. <i>Human Pathology</i> , 2020, 102, 70-78.	1.1	7
203	Renal Cell Carcinoma: genomic landscape and clinical implications. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 95-100.	0.4	1
204	Re: Maria Chiara Sighinolfi, Bernardo Rocco's Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. https://uroweb.org/guideline/prostate-cancer/ . <i>Eur Urol</i> 2019;76:871. <i>European Urology</i> , 2020, 77, e122-e127.	0.9	0
205	Immunotherapy for urothelial cancer: from the diagnostic pathologist's point of view. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 539-544.	1.4	9
206	Outcomes comparison of hydrophilic and non-hydrophilic catheters for patients with intermittent catheterization: An updated meta-analysis. <i>Asian Journal of Surgery</i> , 2020, 43, 633-635.	0.2	7
207	The applicability and utility of immunohistochemical biomarkers in bladder pathology. <i>Human Pathology</i> , 2020, 98, 32-55.	1.1	21
208	A novel estimator of between-study variance in random-effects models. <i>BMC Genomics</i> , 2020, 21, 149.	1.2	1
209	Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors and immunotherapy. <i>Future Oncology</i> , 2020, 16, 75-80.	1.1	11
210	Molecular diagnostics in uro-oncology. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 117-121.	1.5	4
211	Molecular characteristics of testicular germ cell tumors: pathogenesis and mechanisms of therapy resistance. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 75-79.	1.1	11
212	Clinicopathologic analysis of upper urinary tract carcinoma with variant histology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 111-120.	1.4	24
213	Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer. <i>Cells</i> , 2020, 9, 1073.	1.8	34
214	The expanding molecular and mutational landscape of nested variant of urothelial carcinoma. <i>Histopathology</i> , 2020, 76, 638-639.	1.6	7
215	Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications. <i>Frontiers in Genetics</i> , 2020, 11, 349.	1.1	9
216	pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 3-16.	1.4	8

#	ARTICLE	IF	CITATIONS
217	Computational analysis of pathological images enables a better diagnosis of TFE3 Xp11.2 translocation renal cell carcinoma. <i>Nature Communications</i> , 2020, 11, 1778.	5.8	50
218	Prostate Specific Membrane Antigen Targeted Positron Emission Tomography of Primary Prostate Cancer: Assessing Accuracy with Whole Mount Pathology. <i>Journal of Urology</i> , 2020, 203, 92-99.	0.2	15
219	A new survival model based on ferroptosis-related genes for prognostic prediction in clear cell renal cell carcinoma. <i>Aging</i> , 2020, 12, 14933-14948.	1.4	67
220	Analysis of Protein-Protein Interaction Networks through Computational Approaches. <i>Protein and Peptide Letters</i> , 2020, 27, 265-278.	0.4	5
221	Immunotherapy and Radiation Therapy in Renal Cell Carcinoma. <i>Current Drug Targets</i> , 2020, 21, 1463-1475.	1.0	10
222	PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay. <i>Current Drug Targets</i> , 2020, 21, 1664-1671.	1.0	12
223	PD-L1 Inhibitors for the Treatment of Prostate Cancer. <i>Current Drug Targets</i> , 2020, 21, 1558-1565.	1.0	4
224	The Assessment of Interleukin-18 on the Risk of Coronary Heart Disease. <i>Medicinal Chemistry</i> , 2020, 16, 626-634.	0.7	11
225	Staging and Reporting of Renal Cell Carcinomas. , 2020, , 423-436.		0
226	System Biology Methods and Tools for Pharmaceutical Design. <i>Current Pharmaceutical Design</i> , 2020, 26, 3047-3048.	0.9	1
227	Sclerosing Adenosis of the Prostate. <i>Encyclopedia of Pathology</i> , 2020, , 365-366.	0.0	0
228	OntoSem: an Ontology Semantic Representation Methodology for Biomedical Domain. , 2020, , .		2
229	Identification of gene signature associated with type 2 diabetes mellitus by integrating mutation and expression data. , 2020, , .		0
230	Inverted Urothelial Papilloma. <i>Encyclopedia of Pathology</i> , 2020, , 158-161.	0.0	0
231	Pathology of the Benign and Malignant Diseases of the Prostate. , 2020, , 1-12.		0
232	Urothelial Carcinoma In Situ. <i>Encyclopedia of Pathology</i> , 2020, , 460-463.	0.0	0
233	Whole exome and target sequencing identifies MAP2K5 as novel susceptibility gene for familial non-€medullary thyroid carcinoma. <i>International Journal of Cancer</i> , 2019, 144, 1321-1330.	2.3	37
234	Prostate Cancer Grading: Are We Heading Towards Grade Grouping Version 2?. <i>European Urology</i> , 2019, 75, 32-34.	0.9	3

#	ARTICLE	IF	CITATIONS
235	Liquid Biopsy as Surrogate for Tissue for Molecular Profiling in Pancreatic Cancer: A Meta-Analysis Towards Precision Medicine. <i>Cancers</i> , 2019, 11, 1152.	1.7	33
236	Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities. <i>Molecular Oncology</i> , 2019, 13, 2259-2277.	2.1	27
237	Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: where we stand and where we go. <i>Future Oncology</i> , 2019, 15, 2199-2202.	1.1	14
238	Predicting biochemical recurrence after radical prostatectomy: the role of prognostic grade group and index tumor nodule. <i>Human Pathology</i> , 2019, 93, 6-15.	1.1	3
239	Controversial issues in Gleason and International Society of Urological Pathology (ISUP) prostate cancer grading: proposed recommendations for international implementation. <i>Pathology</i> , 2019, 51, 463-473.	0.3	47
240	Computational Methods for Identifying Similar Diseases. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 18, 590-604.	2.3	102
241	Perspectives of lung cancer control and molecular prevention. <i>Future Oncology</i> , 2019, 15, 3527-3530.	1.1	0
242	Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice. <i>Immunotherapy</i> , 2019, 11, 1507-1521.	1.0	17
243	Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers. <i>Cancers</i> , 2019, 11, 1225.	1.7	15
244	Dissecting the molecular landscape of pancreatic cancer: towards a precision medicine approach. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 113-119.	0.4	4
245	Digital versus light microscopy assessment of extraprostatic extension in radical prostatectomy samples. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 735-744.	1.4	3
246	Microstructural and Geomechanical Study on Biocemented Sand for Optimization of MICP Process. <i>Journal of Materials in Civil Engineering</i> , 2019, 31, .	1.3	94
247	Prognostic Role of High-Grade Tumor Budding in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis with a Focus on Epithelial to Mesenchymal Transition. <i>Cancers</i> , 2019, 11, 113.	1.7	45
248	Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter. <i>Therapeutic Advances in Urology</i> , 2019, 11, 175628721881537.	0.9	7
249	Clinicopathological characteristics of ypT0N0 urothelial carcinoma following neoadjuvant chemotherapy and cystectomy. <i>Journal of Clinical Pathology</i> , 2019, 72, 550-553.	1.0	4
250	Plasmacytoid/diffuse urothelial carcinoma: a single-institution immunohistochemical and molecular study of 69 patients. <i>Human Pathology</i> , 2019, 90, 27-36.	1.1	28
251	MYB-NFIB gene fusion in prostatic basal cell carcinoma: clinicopathologic correlates and comparison with basal cell adenoma and florid basal cell hyperplasia. <i>Modern Pathology</i> , 2019, 32, 1666-1674.	2.9	13
252	Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor. <i>Cancers</i> , 2019, 11, 830.	1.7	29

#	ARTICLE	IF	CITATIONS
253	Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 445-455.	1.4	38
254	Expression of miR-100 and miR-138 as prognostic biomarkers in non-muscle-invasive bladder cancer. <i>Apmis</i> , 2019, 127, 545-553.	0.9	20
255	Aberrant ERG expression associates with downregulation of miR-4638 and selected genomic alterations in a subset of diffuse large B-cell lymphoma. <i>Molecular Carcinogenesis</i> , 2019, 58, 1846-1854.	1.3	9
256	Re: Gillian Vandekerckhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. <i>Eur Urol</i> 2019;75:667-75. <i>European Urology</i> , 2019, 76, e69-e72.	0.9	6
257	Identification of Cancer Dysfunctional Subpathways by Integrating DNA Methylation, Copy Number Variation, and Gene-Expression Data. <i>Frontiers in Genetics</i> , 2019, 10, 441.	1.1	27
258	LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling. <i>Nature Communications</i> , 2019, 10, 2571.	5.8	153
259	Editorial: Emerging Biomarkers in Genitourinary Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 326.	1.3	4
260	Distinct mutational landscape of inverted urothelial papilloma. <i>Journal of Pathology</i> , 2019, 249, 3-5.	2.1	14
261	Dysbiosis of the Gut Microbiome in Lung Cancer. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 112.	1.8	138
262	A Positive Causal Influence of IL-18 Levels on the Risk of T2DM: A Mendelian Randomization Study. <i>Frontiers in Genetics</i> , 2019, 10, 295.	1.1	19
263	Activating KRAS mutations in arteriovenous malformations of the brain: frequency and clinicopathologic correlation. <i>Human Pathology</i> , 2019, 89, 33-39.	1.1	45
264	Circulating Tumor Cells in Renal Cell Carcinoma: Recent Findings and Future Challenges. <i>Frontiers in Oncology</i> , 2019, 9, 228.	1.3	20
265	Determining IDH-Mutational Status in Gliomas Using IDH1-R132H Antibody and Polymerase Chain Reaction. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 722-725.	0.6	16
266	Low-grade oncocytic tumour of kidney (CD117-negative, cytokeratin 7-positive): a distinct entity?. <i>Histopathology</i> , 2019, 75, 174-184.	1.6	100
267	Authors' reply to: Absence of the MA <i>P2K5</i> germline variants c.G961A and c.T1100C in a wide series of familial non-medullary thyroid carcinoma Italian families. <i>International Journal of Cancer</i> 2019; in press. <i>International Journal of Cancer</i> , 2019, 145, 601-602.	2.3	3
268	Energy efficient COD and N-removal from high-strength wastewater by a passively aerated GAO dominated biofilm. <i>Bioresource Technology</i> , 2019, 283, 148-158.	4.8	27
269	Alternative lengthening of telomeres (ALT) influences survival in soft tissue sarcomas: a systematic review with meta-analysis. <i>BMC Cancer</i> , 2019, 19, 232.	1.1	37
270	Microbiome and Cancers, With Focus on Genitourinary Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 178.	1.3	20

#	ARTICLE	IF	CITATIONS
271	Molecular evidence supporting the precursor nature of atypical adenomatous hyperplasia of the prostate. <i>Molecular Carcinogenesis</i> , 2019, 58, 1272-1278.	1.3	5
272	Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution. <i>Clinical Drug Investigation</i> , 2019, 39, 503-519.	1.1	26
273	The Human Microbiota and Prostate Cancer: Friend or Foe?. <i>Cancers</i> , 2019, 11, 459.	1.7	38
274	Fine-needle aspiration cytology of metastatic spindle cell follicular thyroid carcinoma: A case report. <i>Diagnostic Cytopathology</i> , 2019, 47, 608-611.	0.5	2
275	Emerging Molecular Technologies in Renal Cell Carcinoma: Liquid Biopsy. <i>Cancers</i> , 2019, 11, 196.	1.7	23
276	Exposing the Causal Effect of Body Mass Index on the Risk of Type 2 Diabetes Mellitus: A Mendelian Randomization Study. <i>Frontiers in Genetics</i> , 2019, 10, 94.	1.1	55
277	Detection of androgen receptor (AR) and AR-V7 in small cell prostate carcinoma: Diagnostic and therapeutic implications. <i>Asian Journal of Urology</i> , 2019, 6, 109-113.	0.5	7
278	Clear Cell Tumors of the Kidney and the Gynecologic Tract. , 2019, , 173-188.		0
279	Transitional Cell Tumors of the Bladder. , 2019, , 254-273.		0
280	Squamotransitional Carcinoma and Transitional Cell Metaplasia of the Cervix and the Vagina, and Squamous Cell Carcinoma and Squamous Lesions of the Urinary Tract. , 2019, , 274-277.		0
281	Micropapillary Urothelial Carcinoma of the Bladder versus Gynecologic Tract Carcinomas with Micropapillary Features: Similarities and Differences. , 2019, , 278-282.		0
282	Pathology of the Female and Male Urethra. , 2019, , 285-303.		0
283	Another one in the chamber: cabozantinib for patients with metastatic non clear cell renal cell carcinoma. <i>Annals of Translational Medicine</i> , 2019, 7, S137-S137.	0.7	9
284	Clinical utility versus futility: a tipping point for liquid biopsies in bladder cancer. <i>Future Oncology</i> , 2019, 15, 3751-3753.	1.1	1
285	A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer. <i>European Urology Oncology</i> , 2019, 2, 294-301.	2.6	38
286	Peptide-Major Histocompatibility Complex Class I Binding Prediction Based on Deep Learning With Novel Feature. <i>Frontiers in Genetics</i> , 2019, 10, 1191.	1.1	21
287	Identifying Alzheimer's disease-related proteins by LRRGD. <i>BMC Bioinformatics</i> , 2019, 20, 570.	1.2	13
288	The Role of Obesity in Renal Cell Carcinoma Patients: Clinical-Pathological Implications. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5683.	1.8	26

#	ARTICLE	IF	CITATIONS
289	Current Progress in CAR-T Cell Therapy for Solid Tumors. <i>International Journal of Biological Sciences</i> , 2019, 15, 2548-2560.	2.6	252
290	Molecular Testing for EGFR Mutations and ALK Rearrangements in the Cytological Specimens From the Patients With Non-Small Cell Lung Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 119-124.	0.6	10
291	Computational and Biological Methods for Gene Therapy. <i>Current Gene Therapy</i> , 2019, 19, 210-210.	0.9	60
292	Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 917-927.	0.6	3
293	Papillary Renal Neoplasm With Reverse Polarity. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1099-1111.	2.1	65
294	Detecting and phenotyping of aneuploid circulating tumor cells in patients with various malignancies. <i>Cancer Biology and Therapy</i> , 2019, 20, 546-551.	1.5	28
295	Molecular characterization of testicular germ cell tumors: chasing the underlying pathways. <i>Future Oncology</i> , 2019, 15, 227-229.	1.1	14
296	Staging of bladder cancer. <i>Histopathology</i> , 2019, 74, 112-134.	1.6	117
297	Renal cell carcinoma staging: pitfalls, challenges, and updates. <i>Histopathology</i> , 2019, 74, 18-30.	1.6	50
298	Variants and new entities of bladder cancer. <i>Histopathology</i> , 2019, 74, 77-96.	1.6	120
299	Annual review issue. <i>Histopathology</i> , 2019, 74, 3-3.	1.6	0
300	The molecular characterization and therapeutic strategies of papillary renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 169-175.	1.1	10
301	RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications. <i>Journal of Clinical Pathology</i> , 2019, 72, 135-139.	1.0	28
302	Re: Friederike Haidl, David Pfister, Axel Heidenreich. Re: Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients. Mordasini L, Hechelhammer L, Diener PA, et al. <i>J Vasc Interv Radiol</i> 2018;29:589-97. <i>Eur Urol</i> 2018;74:525-6. <i>European Urology</i> , 2019, 75, e110-e113.	0.9	3
303	Perineural Invasion is a Strong Prognostic Moderator in Ampulla of Vater Carcinoma. <i>Pancreas</i> , 2019, 48, 70-76.	0.5	11
304	Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer. <i>Cells</i> , 2019, 8, 43.	1.8	38
305	Systematic identification and analysis of dysregulated miRNA and transcription factor feedforward loops in hypertrophic cardiomyopathy. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 306-316.	1.6	20
306	Histopathologic challenges: The second OPINION issue. <i>European Journal of Surgical Oncology</i> , 2019, 45, 12-15.	0.5	8

#	ARTICLE	IF	CITATIONS
307	Soil bio-cementation using a new one-phase low-pH injection method. <i>Acta Geotechnica</i> , 2019, 14, 615-626.	2.9	157
308	LncRNA2Target v2.0: a comprehensive database for target genes of lncRNAs in human and mouse. <i>Nucleic Acids Research</i> , 2019, 47, D140-D144.	6.5	311
309	Detection of driver mutations in BRAF can aid in diagnosis and early treatment of dedifferentiated metastatic melanoma. <i>Modern Pathology</i> , 2019, 32, 330-337.	2.9	18
310	MetSigDis: a manually curated resource for the metabolic signatures of diseases. <i>Briefings in Bioinformatics</i> , 2019, 20, 203-209.	3.2	106
311	Coexpression patterns of IDO-1, PD-L1 and EGFR in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14279-e14279.	0.8	2
312	Identification of a Combined RNA Prognostic Signature in Adenocarcinoma of the Lung. <i>Medical Science Monitor</i> , 2019, 25, 3941-3956.	0.5	5
313	Cylindrical illumination with angular coupling for whole-prostate photoacoustic tomography. <i>Biomedical Optics Express</i> , 2019, 10, 1405.	1.5	8
314	PD-L1 assessment in urothelial carcinoma: a practical approach. <i>Annals of Translational Medicine</i> , 2019, 7, 690-690.	0.7	77
315	A Review of Recent Advances and Research on Drug Target Identification Methods. <i>Current Drug Metabolism</i> , 2019, 20, 209-216.	0.7	23
316	Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy. <i>Current Drug Metabolism</i> , 2019, 20, 305-312.	0.7	11
317	A Mendelian Randomization Study on Infant Length and Type 2 Diabetes Mellitus Risk. <i>Current Gene Therapy</i> , 2019, 19, 224-231.	0.9	15
318	Urothelial Carcinoma in Situ. <i>Encyclopedia of Pathology</i> , 2019, , 1-4.	0.0	0
319	Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians. <i>Asian Journal of Andrology</i> , 2019, 21, 19.	0.8	2
320	Inverted Urothelial Papilloma. <i>Encyclopedia of Pathology</i> , 2019, , 1-4.	0.0	0
321	Sclerosing Adenosis, Genitourinary Tract. <i>Encyclopedia of Pathology</i> , 2019, , 1-2.	0.0	0
322	Extramammary Paget disease of the penis closely mimicking the penile analogue of stratified mucin-producing intraepithelial lesion. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2019, 71, 189-190.	3.9	3
323	Liquid biopsies in renal cell carcinoma with focus on epigenome analysis. <i>Annals of Translational Medicine</i> , 2019, 7, S194-S194.	0.7	1
324	An Immune-Related Six-lncRNA Signature to Improve Prognosis Prediction of Glioblastoma Multiforme. <i>Molecular Neurobiology</i> , 2018, 55, 3684-3697.	1.9	221

#	ARTICLE	IF	CITATIONS
325	Re: A Novel Tool for Predicting Extracapsular Extension During Graded Partial Nerve Sparring in Radical Prostatectomy. <i>European Urology</i> , 2018, 73, 978-980.	0.9	0
326	Unclassified hemangioma-like renal cell carcinoma: a potential diagnostic pitfall. <i>Human Pathology</i> , 2018, 75, 132-136.	1.1	5
327	Digital versus light microscopy assessment of surgical margin status after radical prostatectomy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 451-460.	1.4	9
328	Next-Generation Sequencing to Detect Deletion of RB1 and ERBB4 Genes in Chromophobe Renal Cell Carcinoma. <i>American Journal of Pathology</i> , 2018, 188, 846-852.	1.9	22
329	Immune checkpoint inhibitors for metastatic bladder cancer. <i>Cancer Treatment Reviews</i> , 2018, 64, 11-20.	3.4	76
330	Extranodal extension of nodal metastases is a poor prognostic moderator in non-small cell lung cancer: a meta-analysis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 939-947.	1.4	36
331	Inherited forms of bladder cancer: a review of Lynch syndrome and other inherited conditions. <i>Future Oncology</i> , 2018, 14, 277-290.	1.1	19
332	DincRNA: a comprehensive web-based bioinformatics toolkit for exploring disease associations and ncRNA function. <i>Bioinformatics</i> , 2018, 34, 1953-1956.	1.8	241
333	Renal cell carcinoma with angioleiomyoma-like stroma and clear cell papillary renal cell carcinoma: exploring SDHB protein immunohistochemistry and the relationship to tuberous sclerosis complex. <i>Human Pathology</i> , 2018, 75, 10-15.	1.1	21
334	Intratumoural heterogeneity may hinder precision medicine strategies in patients with clear cell renal cell carcinoma. <i>Journal of Clinical Pathology</i> , 2018, 71, 467-471.	1.0	6
335	Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 279-292.	2.1	101
336	Use of CD42b immunohistochemical stain for the detection of Histoplasma. <i>Annals of Diagnostic Pathology</i> , 2018, 32, 47-50.	0.6	3
337	Identifying diseases-related metabolites using random walk. <i>BMC Bioinformatics</i> , 2018, 19, 116.	1.2	53
338	Mucinous intrahepatic cholangiocarcinoma: a distinct variant. <i>Human Pathology</i> , 2018, 78, 131-137.	1.1	16
339	Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 685-693.	1.1	19
340	Iatrogenic pathology of the urinary bladder. <i>Seminars in Diagnostic Pathology</i> , 2018, 35, 218-227.	1.0	15
341	From Gleason Grading System and High-grade Tertiary Patterns to Grade Groups and Integrated Quantitative Gleason Score. <i>European Urology</i> , 2018, 73, 684-686.	0.9	5
342	Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma. <i>European Urology Focus</i> , 2018, 4, 880-888.	1.6	25

#	ARTICLE	IF	CITATIONS
343	Whole Slide Imaging Versus Microscopy for Primary Diagnosis in Surgical Pathology. <i>American Journal of Surgical Pathology</i> , 2018, 42, 39-52.	2.1	289
344	Morphological spectrum of renal cell carcinoma, unclassified: an analysis of 136 cases. <i>Histopathology</i> , 2018, 72, 305-319.	1.6	41
345	Classical gonadoblastoma: its relationship to the "dissecting"™ variant and undifferentiated gonadal tissue. <i>Histopathology</i> , 2018, 72, 545-555.	1.6	19
346	Vasitis nodosa and related lesions: a modern immunohistochemical staining profile with special emphasis on novel diagnostic dilemmas. <i>Human Pathology</i> , 2018, 73, 164-170.	1.1	6
347	Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. <i>Modern Pathology</i> , 2018, 31, 24-38.	2.9	324
348	Prognostic value of programmed death ligand 1, p53, and Ki-67 in patients with advanced-stage colorectal cancer. <i>Human Pathology</i> , 2018, 71, 20-29.	1.1	33
349	PTEN Expression in Mucinous Prostatic Adenocarcinoma, Prostatic Adenocarcinoma With Mucinous Features, and Adjacent Conventional Prostatic Adenocarcinoma: A Multi-institutional Study of 92 Cases. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 225-230.	0.6	3
350	2185 The effects of autoimmune inflammation on proliferation, differentiation, and androgen receptor signaling in adult prostate stem cells. <i>Journal of Clinical and Translational Science</i> , 2018, 2, 31-31.	0.3	0
351	Quick steps toward precision medicine in renal cell carcinoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018, 3, 283-285.	0.4	0
352	Upper urinary tract urothelial carcinoma and its variants: transition from morphology to personalized molecular characterization in diagnosis, prognosis, and therapy. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 1021-1028.	1.5	8
353	The Identification of Immunological Biomarkers in Kidney Cancers. <i>Frontiers in Oncology</i> , 2018, 8, 456.	1.3	40
354	Exposing the Causal Effect of C-Reactive Protein on the Risk of Type 2 Diabetes Mellitus: A Mendelian Randomization Study. <i>Frontiers in Genetics</i> , 2018, 9, 657.	1.1	70
355	Proof of concept of wastewater treatment via passive aeration SND using a novel zeolite amended biofilm reactor. <i>Water Science and Technology</i> , 2018, 78, 2204-2213.	1.2	8
356	Emerging Prognostic Biomarkers in Testicular Germ Cell Tumors: Looking Beyond Established Practice. <i>Frontiers in Oncology</i> , 2018, 8, 571.	1.3	19
357	Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 397.	1.3	20
358	Testicular cancer. <i>Nature Reviews Disease Primers</i> , 2018, 4, 29.	18.1	299
359	Clues to recognition of fumarate hydratase-deficient renal cell carcinoma: Findings from cytologic and limited biopsy samples. <i>Cancer Cytopathology</i> , 2018, 126, 992-1002.	1.4	9
360	Human Disease System Biology. <i>Current Gene Therapy</i> , 2018, 18, 255-256.	0.9	44

#	ARTICLE	IF	CITATIONS
361	Cyclic hydrostatic pressure promotes uroplakin expression in human urothelial cells through activation of ERK1/2 signaling. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 2499-2503.	1.0	5
362	Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 10094-10099.	3.3	102
363	Immunotherapy in renal cell carcinoma: latest evidence and clinical implications. <i>Drugs in Context</i> , 2018, 7, 1-8.	1.0	63
364	Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 131, 1-6.	2.0	10
365	Prostate cancer grading in 2018: limitations, implementations, cribriform morphology, and biological markers. <i>International Journal of Biological Markers</i> , 2018, 33, 331-334.	0.7	10
366	Physiological stretch induced proliferation of human urothelial cells via integrin $\beta 6$ /FAK signaling pathway. <i>Neurourology and Urodynamics</i> , 2018, 37, 2114-2120.	0.8	9
367	Benign vascular tumors, cysts, and pseudocysts of the adrenal gland: a contemporary multi-institutional clinicopathological analysis of 55 cases. <i>Human Pathology</i> , 2018, 82, 95-102.	1.1	13
368	Immunohistochemical characteristics of renomedullary interstitial cell tumor: a study of 41 tumors with emphasis on differential diagnosis of mesenchymal neoplasms. <i>Human Pathology</i> , 2018, 82, 46-50.	1.1	4
369	Protein expression of the transcription factors DMRT1, TCF5, and OCT4 in selected germ cell neoplasms of the testis. <i>Human Pathology</i> , 2018, 82, 68-75.	1.1	6
370	Exploring Small Extracellular Vesicles for Precision Medicine in Prostate Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 221.	1.3	24
371	PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: expression patterns and clinical implications. <i>Human Pathology</i> , 2018, 81, 157-165.	1.1	44
372	InfAcrOnt: calculating cross-ontology term similarities using information flow by a random walk. <i>BMC Genomics</i> , 2018, 19, 919.	1.2	98
373	An ovulating follicle presenting as a testicular mass in a teenage patient with ovotesticular DSD. <i>Urology Case Reports</i> , 2018, 18, 26-28.	0.1	3
374	Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer. <i>Future Oncology</i> , 2018, 14, 2559-2564.	1.1	6
375	Re: Isabel Rauscher, Charlotte DÄ4wel, Bernhard Haller, et al. Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-Äligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. <i>Eur Urol</i> 2018;73:656Ä61. <i>European Urology</i> , 2018, 74, e141-e144.	0.9	3
376	Photoacoustic tomography of intact human prostates and vascular texture analysis identify prostate cancer biopsy targets. <i>Photoacoustics</i> , 2018, 11, 46-55.	4.4	22
377	Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype. <i>Human Pathology</i> , 2018, 80, 55-64.	1.1	36
378	Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies. <i>Cancer Treatment Reviews</i> , 2018, 68, 80-85.	3.4	27

#	ARTICLE	IF	CITATIONS
379	Challenges in Pathologic Staging of Renal Cell Carcinoma. American Journal of Surgical Pathology, 2018, 42, 1253-1261.	2.1	22
380	Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer. Expert Review of Molecular Diagnostics, 2018, 18, 645-655.	1.5	20
381	Identification of Alzheimer's Disease-Related Genes Based on Data Integration Method. Frontiers in Genetics, 2018, 9, 703.	1.1	42
382	LBA21 PHASE 2 CLINICAL TRIAL IN PROSTATE CANCER EVALUATING 68 GA-PSMA-11 DETECTION ON BOTH PREOPERATIVE PET-CT AND IMMEDIATE POSTOPERATIVE SPECIMEN SCANNING. Journal of Urology, 2018, 199, .	0.2	1
383	Plasmacytoid urothelial carcinoma: A clinicopathological study.. Journal of Clinical Oncology, 2018, 36, 482-482.	0.8	5
384	Human Disease-Protein Network. Current Proteomics, 2018, 15, 159-164.	0.1	0
385	Prognostic role of BRAF mutation in malignant cutaneous melanoma.. Journal of Clinical Oncology, 2018, 36, e21599-e21599.	0.8	3
386	Survival outcomes in plasmacytoid urothelial carcinoma: Results with contemporary systemic therapy.. Journal of Clinical Oncology, 2018, 36, e16525-e16525.	0.8	0
387	Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients. World Journal of Urology, 2017, 35, 517-526.	1.2	16
388	Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma. Applied Immunohistochemistry and Molecular Morphology, 2017, 25, 39-43.	0.6	8
389	Prognostic Effect of Carcinoma In Situ in Muscle-invasive Urothelial Carcinoma Patients Receiving Neoadjuvant Chemotherapy. Clinical Genitourinary Cancer, 2017, 15, 479-486.	0.9	5
390	Unclassified Renal Cell Carcinoma With Significant Response to Nivolumab. Clinical Genitourinary Cancer, 2017, 15, e517-e519.	0.9	5
391	TERT Promoter Mutations Occur Frequently in Urothelial Papilloma and Papillary Urothelial Neoplasm of Low Malignant Potential. European Urology, 2017, 71, 497-498.	0.9	35
392	<i>TERT</i> promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract. Future Oncology, 2017, 13, 705-714.	1.1	22
393	TMPRSS2-ERG Fusion in an Uncommon Presentation of Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, e489-e491.	0.9	0
394	Tp53 and its potential therapeutic role as a target in bladder cancer. Expert Opinion on Therapeutic Targets, 2017, 21, 401-414.	1.5	28
395	Predicting disease-related genes using integrated biomedical networks. BMC Genomics, 2017, 18, 1043.	1.2	46
396	Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma. Molecular Cancer, 2017, 16, 16.	7.9	227

#	ARTICLE	IF	CITATIONS
397	Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets. <i>Future Oncology</i> , 2017, 13, 1105-1114.	1.1	4
398	GAB2 rs2373115 variant contributes to Alzheimer's disease risk specifically in European population. <i>Journal of the Neurological Sciences</i> , 2017, 375, 18-22.	0.3	43
399	Solitary fibrous tumour of the genitourinary tract: a clinicopathological study of 11 cases and their association with the <i>NAB2-STAT6</i> fusion gene. <i>Journal of Clinical Pathology</i> , 2017, 70, 508-514.	1.0	20
400	Perspectives on testicular sex cord-stromal tumors and those composed of both germ cells and sex cord-stromal derivatives with a comparison to corresponding ovarian neoplasms. <i>Human Pathology</i> , 2017, 65, 1-14.	1.1	24
401	Lymphoepithelioma-like carcinoma of the upper urinary tract. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 703-709.	1.4	22
402	Primary Cystic Trophoblastic Tumor of the Testis. <i>American Journal of Surgical Pathology</i> , 2017, 41, 788-794.	2.1	15
403	Fluorescence <i>in situ</i> hybridization in surgical pathology: principles and applications. <i>Journal of Pathology: Clinical Research</i> , 2017, 3, 73-99.	1.3	33
404	Renal Cell Carcinoma With Chromosome 6p Amplification Including the <i>TFEB</i> Gene. <i>American Journal of Surgical Pathology</i> , 2017, 41, 287-298.	2.1	60
405	Renal cell carcinoma with <i>TFE3</i> translocation and succinate dehydrogenase B mutation. <i>Modern Pathology</i> , 2017, 30, 407-415.	2.9	28
406	Rhabdoid and Undifferentiated Phenotype in Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2017, 41, 253-262.	2.1	56
407	Extranodal extension of lymph node metastasis influences recurrence in prostate cancer: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2017, 7, 2374.	1.6	30
408	Re: Umberto Leone Roberti Maggiore, Simone Ferrero, Massimo Candiani, et al. Bladder Endometriosis: A Systematic Review of Pathogenesis, Diagnosis, Treatment, Impact on Fertility, and Risk of Malignant Transformation. <i>Eur Urol</i> 2017;71:790-807. <i>European Urology</i> , 2017, 72, e139-e141.	0.9	1
409	Pathology and molecular updates in tumors of the prostate: towards a personalized approach. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 781-789.	1.5	9
410	Diagnostic utility of <i>IDH1/2</i> mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone. <i>Human Pathology</i> , 2017, 65, 239-246.	1.1	50
411	Understanding the Genetic Landscape of Small Cell Carcinoma of the Urinary Bladder and Implications for Diagnosis, Prognosis, and Treatment. <i>JAMA Oncology</i> , 2017, 3, 1570.	3.4	38
412	On the histogenesis of mixed germ cell-sex cord stromal tumour of the gonads. <i>Journal of Clinical Pathology</i> , 2017, 70, 222-227.	1.0	10
413	A contemporary series of renal masses with emphasis on recently recognized entities and tumors of low malignant potential: A report based on 624 consecutive tumors from a single tertiary center. <i>Pathology Research and Practice</i> , 2017, 213, 804-808. Re: Kenneth A. Iczkowski's Letter to the Editor re: Re: Rodolfo Montironi, Silvia Gasparrini, Roberta Mazzucchelli, et al's Letter to the Editor re: Karim A. Touijer, James A. Eastham. <i>The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer. Eur Urol</i> 2016;70:738-9: Sentinel Lymph Nodes in Adipose Tissue Surrounding the Prostate Gland and Seminal Vesicles as Observed in Virtual Whole-mount Histologic Slides. <i>Eur Urol</i> 2017;71:e73-5. <i>European Urology</i> , 2017, 72, e37-e38.	1.0	10
414	Re: Kenneth A. Iczkowski's Letter to the Editor re: Re: Rodolfo Montironi, Silvia Gasparrini, Roberta Mazzucchelli, et al's Letter to the Editor re: Karim A. Touijer, James A. Eastham. <i>The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer. Eur Urol</i> 2016;70:738-9: Sentinel Lymph Nodes in Adipose Tissue Surrounding the Prostate Gland and Seminal Vesicles as Observed in Virtual Whole-mount Histologic Slides. <i>Eur Urol</i> 2017;71:e73-5. <i>European Urology</i> , 2017, 72, e37-e38.	0.9	2

#	ARTICLE	IF	CITATIONS
415	Diagnostic criteria for oncocytic renal neoplasms: a survey of urologic pathologists. <i>Human Pathology</i> , 2017, 63, 149-156.	1.1	89
416	Considerations for standardizing predictive molecular pathology for cancer prognosis. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 47-55.	1.5	3
417	A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <i>FGFR3</i> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157. <i>Clinical Cancer Research</i> , 2017, 23, 3003-3011.	3.2	59
418	Validation of 34betaE12 immunoexpression in clear cell papillary renal cell carcinoma as a sensitive biomarker. <i>Pathology</i> , 2017, 49, 10-18.	0.3	30
419	Iatrogenic changes in the urinary tract. <i>Histopathology</i> , 2017, 70, 10-25.	1.6	25
420	Activity and Functions of Tumor-associated Macrophages in Prostate Carcinogenesis. <i>European Urology Supplements</i> , 2017, 16, 301-308.	0.1	6
421	Reply to Chou et al "Do significant TFE3 gene rearrangements occur in succinate dehydrogenase deficient renal cell carcinoma? Borderline FISH results should be interpreted with caution" <i>Mod Pathol</i> 2017; in press.. <i>Modern Pathology</i> , 2017, 30, 1509-1511.	2.9	4
422	Variants and Variations in Epithelial Renal Cell Tumors in Adults: The Pathologist's Point of View. <i>European Urology Supplements</i> , 2017, 16, 232-240.	0.1	3
423	Morphologic Variants of Epithelial and Neuroendocrine Tumors of the Prostate. The Pathologist's Point of View. <i>European Urology Supplements</i> , 2017, 16, 223-231.	0.1	4
424	Variants of Bladder Cancer: The Pathologist's Point of View. <i>European Urology Supplements</i> , 2017, 16, 210-222.	0.1	16
425	Complexity of the genomic landscape of renal cell carcinoma: Implications for targeted therapy and precision immuno-oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 119, 23-28.	2.0	17
426	Oligometastases in Genitourinary Tumors: Recent Insights and Future Molecular Diagnostic Approach. <i>European Urology Supplements</i> , 2017, 16, 309-315.	0.1	10
427	Autoimmune disease variants regulate <i>GSDMB</i> gene expression in human immune cells and whole blood. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E7860-E7862.	3.3	30
428	Immunotherapy in genitourinary cancers: where are we going?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 73-78.	0.4	2
429	Müllerian Adenosarcoma of the Urinary Bladder: Clinicopathologic and Immunohistochemical Features With Novel Genetic Aberrations. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e1007-e1014.	0.9	5
430	Preservation of truncal genomic alterations in clear cell and papillary renal cell carcinomas with sarcomatoid features: An intra- and intertumoral, multifocal fluorescence in situ hybridization analysis reveals limited genetic heterogeneity. <i>Molecular Carcinogenesis</i> , 2017, 56, 2527-2537.	1.3	5
431	Concomitant bladder cancer and prostate cancer: challenges and controversies. <i>Nature Reviews Urology</i> , 2017, 14, 620-629.	1.9	17
432	Whole Slide Imaging of Large Format Histology in Prostate Pathology: Potential for Information Fusion. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 1460-1461.	1.2	13

#	ARTICLE	IF	CITATIONS
433	Rs4878104 contributes to Alzheimer's disease risk and regulates DAPK1 gene expression. <i>Neurological Sciences</i> , 2017, 38, 1255-1262.	0.9	29
434	Testicular cancer: The usage of central review for pathology diagnosis of orchiectomy specimens. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 605.e9-605.e16.	0.8	15
435	Primary Choriocarcinoma of the Bladder: A Case Report and Review of Literature. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 188-191.	0.9	11
436	Re: Daniel M. Geynisman. Anti-programmed cell death protein 1 (PD-1) antibody nivolumab leads to a dramatic and rapid response in papillary renal cell carcinoma with sarcomatoid and rhabdoid features. <i>Eur Urol</i> 2015;68:912-4. <i>European Urology</i> , 2017, 71, e27-e28.	0.9	1
437	Evidence of a dual histogenetic pathway of sacrococcygeal teratomas. <i>Histopathology</i> , 2017, 70, 290-300.	1.6	14
438	<i>TMPRSS2-ERG</i> gene fusion is rare compared to <i>PTEN</i> deletions in stage T1a prostate cancer. <i>Molecular Carcinogenesis</i> , 2017, 56, 814-820.	1.3	6
439	Re: Karim A. Toujjer, James A. Eastham. The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer. <i>Eur Urol</i> 2016;70:738-9. <i>European Urology</i> , 2017, 71, e73-e75.	0.9	6
440	Quantitative Image Analysis on Histologic Virtual Slides for Prostate Pathology Diagnosis, Response to Chemopreventive Agents, and Prognosis. <i>European Urology Focus</i> , 2017, 3, 467-469.	1.6	8
441	Perspectives on testicular germ cell neoplasms. <i>Human Pathology</i> , 2017, 59, 10-25.	1.1	55
442	Identifying diseases-related metabolites based on network. , 2017, , .		0
443	Long Non-coding RNAs in Prostate Cancer with Emphasis on Second Chromosome Locus Associated with Prostate-1 Expression. <i>Frontiers in Oncology</i> , 2017, 7, 305.	1.3	20
444	Measuring disease similarity and predicting disease-related ncRNAs by a novel method. <i>BMC Medical Genomics</i> , 2017, 10, 71.	0.7	49
445	DisSetSim: an online system for calculating similarity between disease sets. <i>Journal of Biomedical Semantics</i> , 2017, 8, 28.	0.9	17
446	A novel method to identify pre-microRNA in various species knowledge base on various species. <i>Journal of Biomedical Semantics</i> , 2017, 8, 30.	0.9	8
447	In reply to: letter to the editor entitled: primary pure lymphoepithelioma-like carcinoma of the ureter. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 561-562.	1.4	0
448	Editorial: Emerging Biomarkers in Genitourinary Tumors. <i>Current Drug Metabolism</i> , 2017, 18, 690-691.	0.7	2
449	Predicting the biological behavior of non-muscle-invasive bladder cancer: from histology to molecular taxonomy. <i>Translational Andrology and Urology</i> , 2017, 6, 987-990.	0.6	1
450	Liquid Biopsies in the Management of Bladder Cancer: Next-Generation Biomarkers for Diagnosis, Surveillance, and Treatment-Response Prediction. <i>Critical Reviews in Oncogenesis</i> , 2017, 22, 389-401.	0.2	7

#	ARTICLE	IF	CITATIONS
451	Epigenetic Modifications and Modulators in Prostate Cancer. <i>Critical Reviews in Oncogenesis</i> , 2017, 22, 439-450.	0.2	14
452	Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation. <i>Oncotarget</i> , 2017, 8, 54096-54105.	0.8	22
453	Estrogen deficiency is associated with hippocampal morphological remodeling of early postmenopausal mice. <i>Oncotarget</i> , 2017, 8, 21892-21902.	0.8	13
454	Prognostic and clinicopathological role of long non-coding RNA UCA1 in various carcinomas. <i>Oncotarget</i> , 2017, 8, 28373-28384.	0.8	19
455	Long non-coding RNAs in renal cell carcinoma: A systematic review and clinical implications. <i>Oncotarget</i> , 2017, 8, 48424-48435.	0.8	38
456	Urinary Biomarkers for Prostate Cancer. <i>Current Drug Metabolism</i> , 2017, 18, 723-726.	0.7	3
457	Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives. <i>Current Drug Metabolism</i> , 2017, 18, 700-711.	0.7	25
458	Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?. <i>Current Drug Metabolism</i> , 2017, 18, 692-699.	0.7	7
459	Mirna Expression in Bladder Cancer and Their Potential Role in Clinical Practice. <i>Current Drug Metabolism</i> , 2017, 18, 712-722.	0.7	31
460	Prostate Cancer Biomarkers: Current Status. <i>Critical Reviews in Oncogenesis</i> , 2017, 22, 253-269.	0.2	3
461	A framework for exploring associations between biomedical terms in PubMed. <i>Oncotarget</i> , 2017, 8, 103100-103107.	0.8	0
462	Genitourinary Cancers: Molecular Determinants for Personalized Therapies. <i>Urologia</i> , 2016, 83, 107-109.	0.3	2
463	Annotating the Function of the Human Genome with Gene Ontology and Disease Ontology. <i>BioMed Research International</i> , 2016, 2016, 1-8.	0.9	16
464	Emerging Immunotargets in Metastatic Renal Cell Carcinoma. <i>Current Drug Targets</i> , 2016, 17, 771-776.	1.0	20
465	Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence. <i>Cancer Biomarkers</i> , 2016, 17, 83-88.	0.8	15
466	Editorial (Thematic Issue: Emerging Immunotargets in Genitourinary Tumors). <i>Current Drug Targets</i> , 2016, 17, 748-749.	1.0	4
467	Construction and analysis of dysregulated lncRNA-associated ceRNA network identified novel lncRNA biomarkers for early diagnosis of human pancreatic cancer. <i>Oncotarget</i> , 2016, 7, 56383-56394.	0.8	155
468	Characterization of long non-coding RNA-associated ceRNA network to reveal potential prognostic lncRNA biomarkers in human ovarian cancer. <i>Oncotarget</i> , 2016, 7, 12598-12611.	0.8	218

#	ARTICLE	IF	CITATIONS
469	Relapse-related long non-coding RNA signature to improve prognosis prediction of lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 29720-29738.	0.8	80
470	Integration of Multiple Genomic and Phenotype Data to Infer Novel miRNA-Disease Associations. <i>PLoS ONE</i> , 2016, 11, e0148521.	1.1	26
471	BLAT2DOLite: An Online System for Identifying Significant Relationships between Genetic Sequences and Diseases. <i>PLoS ONE</i> , 2016, 11, e0157274.	1.1	2
472	Studying Dynamic Features in Myocardial Infarction Progression by Integrating miRNA-Transcription Factor Co-Regulatory Networks and Time-Series RNA Expression Data from Peripheral Blood Mononuclear Cells. <i>PLoS ONE</i> , 2016, 11, e0158638.	1.1	7
473	Neuroendocrine Tumors of the Urinary Bladder According to the 2016 World Health Organization Classification: Molecular and Clinical Characteristics. <i>Endocrine Pathology</i> , 2016, 27, 188-199.	5.2	49
474	Prostate cancer glands with cribriform architecture and with glomeruloid features should be considered as Gleason pattern 4 and not pattern 3. <i>Future Oncology</i> , 2016, 12, 1431-1433.	1.1	5
475	Widespread telomere instability in prostatic lesions. <i>Molecular Carcinogenesis</i> , 2016, 55, 842-852.	1.3	16
476	Cervical Carcinomas With Neuroendocrine Differentiation. <i>International Journal of Gynecological Pathology</i> , 2016, 35, 372-384.	0.9	10
477	Telomerase reverse transcriptase (<sc>TERT</sc>) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change. <i>Histopathology</i> , 2016, 69, 107-113.	1.6	54
478	Different prognostic roles of tumor suppressor gene <i>BAP1</i> in cancer: A systematic review with meta-analysis. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 741-749.	1.5	58
479	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Melanoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 355-357.	1.2	9
480	Multiple and bilateral kidney tumors with clear cells of three different histotypes: A case report with clinicopathologic and molecular study. <i>Apmis</i> , 2016, 124, 619-623.	0.9	6
481	Early detection of prostate cancer: can we have our cake and eat it too?. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 247-249.	1.1	3
482	DisSim: an online system for exploring significant similar diseases and exhibiting potential therapeutic drugs. <i>Scientific Reports</i> , 2016, 6, 30024.	1.6	53
483	Extranodal extension of lymph node metastasis is a marker of poor prognosis in oesophageal cancer: a systematic review with meta-analysis. <i>Journal of Clinical Pathology</i> , 2016, 69, 956-961.	1.0	30
484	Genetic mutations in accordance with a low malignant potential tumour are not demonstrated in clear cell papillary renal cell carcinoma. <i>Journal of Clinical Pathology</i> , 2016, 69, 547-550.	1.0	12
485	DisSetSim: An online system for calculating similarity between disease sets. , 2016, , .		2
486	A novel method to identify pre-microRNA in various species knowledge base. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
487	InfDisSim: A novel method for measuring disease similarity based on information flow. , 2016, , .		2
488	Synchronous clear cell renal cell carcinoma and multilocular cystic renal cell neoplasia of low malignant potential: A clinico-pathologic and molecular study. Pathology Research and Practice, 2016, 212, 471-474.	1.0	2
489	Ambient ionization mass spectrometric analysis of human surgical specimens to distinguish renal cell carcinoma from healthy renal tissue. Analytical and Bioanalytical Chemistry, 2016, 408, 5407-5414.	1.9	43
490	Re: Idir Ouzaid and Karim Bensalah. Results of the First Trial Assessing Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma Do Not reASSURE. Eur Urol 2015;68:542-543. European Urology, 2016, 70, e69-e70.	0.9	0
491	Cysts and Epithelial Proliferations of the Testicular Collecting System. , 2016, , 171-189.		1
492	T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-II β , survivin, and E-cadherin. Human Pathology, 2016, 57, 78-84.	1.1	24
493	High fidelity of driver chromosomal alterations among primary and metastatic renal cell carcinomas: implications for tumor clonal evolution and treatment. Modern Pathology, 2016, 29, 1347-1357.	2.9	8
494	Emerging trends in the evaluation and management of small cell prostate cancer: a clinical and molecular perspective. Expert Review of Anticancer Therapy, 2016, 16, 1029-1037.	1.1	9
495	Loss of expression of the SWI/SNF complex is a frequent event in undifferentiated/dedifferentiated urothelial carcinoma of the urinary tract. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 321-330.	1.4	58
496	Extranodal Extension of Nodal Metastases Is a Poor Prognostic Indicator in Gastric Cancer: a Systematic Review and Meta-analysis. Journal of Gastrointestinal Surgery, 2016, 20, 1692-1698.	0.9	41
497	Immunotargeting and personalized therapies in genitourinary cancers. Future Oncology, 2016, 12, 1853-1856.	1.1	6
498	A potential panel of six-long non-coding RNA signature to improve survival prediction of diffuse large-B-cell lymphoma. Scientific Reports, 2016, 6, 27842.	1.6	65
499	OAHG: an integrated resource for annotating human genes with multi-level ontologies. Scientific Reports, 2016, 6, 34820.	1.6	106
500	Atypical Renal Cysts. American Journal of Surgical Pathology, 2016, 40, 202-211.	2.1	17
501	Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci. American Journal of Surgical Pathology, 2016, 40, 1457-1472.	2.1	112
502	Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. Histopathology, 2016, 69, 441-449.	1.6	82
503	Clinical impact of tumoral angiogenesis on renal cell carcinoma management: where do we stand?. Expert Review of Precision Medicine and Drug Development, 2016, 1, 229-231.	0.4	4
504	Testing PD-1/PD-L1 Expression in Cancer Therapy: Pathologic Insights and Economic Sustainability. Archives of Pathology and Laboratory Medicine, 2016, 140, 501-502.	1.2	11

#	ARTICLE	IF	CITATIONS
505	Neoadjuvant chemotherapy in urothelial bladder cancer: impact of regimen and variant histology. <i>Future Oncology</i> , 2016, 12, 1795-1804.	1.1	11
506	Cholesterol Sulfonation Enzyme, SULT2B1b, Modulates AR and Cell Growth Properties in Prostate Cancer. <i>Molecular Cancer Research</i> , 2016, 14, 776-786.	1.5	24
507	Tubulocystic renal cell carcinoma is an entity that is immunohistochemically and genetically distinct from papillary renal cell carcinoma. <i>Histopathology</i> , 2016, 68, 850-857.	1.6	32
508	Primary mucinous adenocarcinoma of the female urethra: a contemporary clinicopathologic analysis. <i>Human Pathology</i> , 2016, 47, 132-137.	1.1	20
509	GT198 Expression Defines Mutant Tumor Stroma in Human Breast Cancer. <i>American Journal of Pathology</i> , 2016, 186, 1340-1350.	1.9	16
510	SMARCB1/INI1 Genetic Alterations in Renal Medullary Carcinomas. <i>European Urology</i> , 2016, 69, 1062-1064.	0.9	17
511	Pathology and Genetics: Tumours of the Urinary System and Male Genital System. <i>European Urology</i> , 2016, 70, 120-123.	0.9	65
512	Clear cell renal cell tumors: Not all that is "clear" is cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 292.e17-292.e22.	0.8	20
513	Prostate cancer: from Gleason scoring to prognostic grade grouping. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 433-440.	1.1	26
514	FGFR3 and Cyclin D3 as urine biomarkers of bladder cancer recurrence. <i>Biomarkers in Medicine</i> , 2016, 10, 243-253.	0.6	23
515	Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 175-181.	1.6	30
516	Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification. <i>Endocrine Pathology</i> , 2016, 27, 123-135.	5.2	63
517	Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 111-117.	1.6	77
518	Metabolic phenotype of bladder cancer. <i>Cancer Treatment Reviews</i> , 2016, 45, 46-57.	3.4	201
519	Re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. <i>Eur Urol</i> 2015;68:912-4. <i>European Urology</i> , 2016, 70, e72-e74.	0.9	6
520	The utility of CDX2, GATA3, and DOG1 in the diagnosis of testicular neoplasms: an immunohistochemical study of 109 cases. <i>Human Pathology</i> , 2016, 48, 18-24.	1.1	28
521	Mixed germ cell "sex cord stromal tumor of the testis with an intratubular component: a problem in differential diagnosis. <i>Human Pathology</i> , 2016, 51, 51-56.	1.1	8
522	Prevalence and management of prostate cancer among East Asian men: Current trends and future perspectives. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 58.e1-58.e9.	0.8	17

#	ARTICLE	IF	CITATIONS
523	Chromosome 12p abnormalities and IMP3 expression in prepubertal pure testicular teratomas. Human Pathology, 2016, 49, 54-60.	1.1	16
524	Current Histopathologic and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies. European Urology, 2016, 69, 186-190.	0.9	18
525	IntNetLncSim: an integrative network analysis method to infer human lncRNA functional similarity. Oncotarget, 2016, 7, 47864-47874.	0.8	51
526	Metabolic Alterations in Renal and Prostate Cancer. Current Drug Metabolism, 2016, 17, 150-155.	0.7	19
527	An Overview of Emerging Immunotargets of Genitourinary Tumors. Current Drug Targets, 2016, 17, 750-756.	1.0	13
528	Emerging Immunotargets in Bladder Cancer. Current Drug Targets, 2016, 17, 757-770.	1.0	9
529	Emerging Immunotargets and Immunotherapies in Prostate Cancer. Current Drug Targets, 2016, 17, 777-782.	1.0	10
530	Molecular genetics and immunohistochemistry characterization of uncommon and recently described renal cell carcinomas. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2016, 28, 29-49.	0.7	12
531	Urinary Bladder. , 2016, , 1681-1735.		0
532	Prostate. , 2016, , 1751-1788.		0
533	Identification of novel immunomodulatory tumor biology through comprehensive characterization of a metastases-specific epigenome in patients with metachronous primary and metastatic urothelial carcinoma (UC) tumor pairs.. Journal of Clinical Oncology, 2016, 34, 452-452.	0.8	20
534	Renal Pelvis, Ureter, and Urethra. , 2016, , 1737-1750.		0
535	Phase 2 trial of dovitinib in Bacillus Calmette-Guerin (BCG) refractory urothelial carcinoma (UC) with tumor FGFR3 mutations or over-expression: Hoosier Cancer Research Network GU12-157.. Journal of Clinical Oncology, 2016, 34, 4526-4526.	0.8	3
536	Human papillomavirus (HPV)-induced neoplasia in the urinary bladder: a missing link?. Histology and Histopathology, 2016, 31, 595-600.	0.5	8
537	Re: Epithelial-to-mesenchymal Transition in Renal Neoplasms. European Urology, 2015, 68, 736-737.	0.9	10
538	A potential prognostic long non-coding RNA signature to predict metastasis-free survival of breast cancer patients. Scientific Reports, 2015, 5, 16553.	1.6	99
539	Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma. Journal of Experimental and Clinical Cancer Research, 2015, 34, 102.	3.5	207
540	Clear Cell Renal Cell Carcinoma With Borderline Features of Clear Cell Papillary Renal Cell Carcinoma. American Journal of Surgical Pathology, 2015, 39, 1502-1510.	2.1	55

#	ARTICLE	IF	CITATIONS
541	Expression of Transcription Factors and Nuclear Receptors in Mixed Germ Cell-Sex Cord Stromal Tumor and Related Tumors of the Gonads. <i>International Journal of Gynecological Pathology</i> , 2015, 34, 528-534.	0.9	7
542	Uroplakin II (UPII), GATA3, and p40 are Highly Sensitive Markers for the Differential Diagnosis of Invasive Urothelial Carcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2015, 23, 711-716.	0.6	45
543	Do Clear Cell Papillary Renal Cell Carcinomas Have Malignant Potential?. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1621-1634.	2.1	59
544	Diagnosis of "Poorly Formed Glands" Gleason Pattern 4 Prostatic Adenocarcinoma on Needle Biopsy. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1331-1339.	2.1	67
545	Is <i>ALK</i> gene rearrangement overlooked in primary gastrointestinal <i>T</i> cell lymphomas? About two cases. <i>Pathology International</i> , 2015, 65, 666-670.	0.6	4
546	Inflammatory myofibroblastic tumour of the urinary bladder: the role of immunoglobulin G4 and the comparison of two immunohistochemical antibodies and fluorescence <i>in situ</i> hybridization for the detection of anaplastic lymphoma kinase alterations. <i>Histopathology</i> , 2015, 67, 20-38.	1.6	19
547	Correcting the Shrinkage Effects of Formalin Fixation and Tissue Processing for Renal Tumors: toward Standardization of Pathological Reporting of Tumor Size. <i>Journal of Cancer</i> , 2015, 6, 759-766.	1.2	94
548	Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder. <i>PLoS ONE</i> , 2015, 10, e0127908.	1.1	21
549	Editorial (Mini-Thematic Issue: Morphological and Molecular Backgrounds for Personalized Therapies) <i>Tj ETQq1 1 0.784314 rgBT /Ove</i>	1.0	1
550	New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials. <i>Cancer Treatment Reviews</i> , 2015, 41, 614-622.	3.4	19
551	Small renal masses in the era of personalized medicine: Tumor heterogeneity, growth kinetics, and risk of metastasis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 303-309.	0.8	16
552	The Prostate and Seminal Vesicles. , 2015, , 195-310.		1
553	Present and future of personalized medicine in adult genitourinary tumors. <i>Future Oncology</i> , 2015, 11, 1381-1388.	1.1	10
554	Unlike in clear cell renal cell carcinoma, KRAS is not mutated in multilocular cystic clear cell renal cell neoplasm of low potential. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 467, 687-693.	1.4	13
555	Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1367-1369.	1.1	23
556	Pulmonary adenocarcinoma with combined <i>ALK</i> translocation and copy number gain: a rare case with treatment response. <i>Lung Cancer Management</i> , 2015, 4, 125-129.	1.5	1
557	Role of STAT3 pathway in genitourinary tumors. <i>Future Science OA</i> , 2015, 1, FSO15.	0.9	58
558	Feasibility of Omitting Cortical Renorrhaphy During Robot-Assisted Partial Nephrectomy: A Matched Analysis. <i>Journal of Endourology</i> , 2015, 29, 548-555.	1.1	58

#	ARTICLE	IF	CITATIONS
559	Effects of tertiary Gleason pattern 5 on oncological outcome. <i>Nature Reviews Urology</i> , 2015, 12, 188-189.	1.9	2
560	The route to personalized medicine in bladder cancer: where do we stand?. <i>Targeted Oncology</i> , 2015, 10, 325-336.	1.7	14
561	A Better Understanding of the Morphological Features and Molecular Characteristics of Intraductal Carcinoma Helps Clinicians Further Explain Prostate Cancer Aggressiveness. <i>European Urology</i> , 2015, 67, 504-507.	0.9	8
562	Do clear cell papillary renal cell carcinomas occur in patients with von Hippel-Lindau disease?. <i>Human Pathology</i> , 2015, 46, 340-341.	1.1	13
563	Diagnosis and Management of Urothelial Carcinoma In Situ of the Lower Urinary Tract: A Systematic Review. <i>European Urology</i> , 2015, 67, 876-888.	0.9	72
564	Three-tiered nodal classification system for bladder cancer: a new proposal. <i>Future Oncology</i> , 2015, 11, 399-408.	1.1	4
565	Testis and Paratesticular Tissues. , 2015, , 465-480.		2
566	Urinary Bladder and Urachus. , 2015, , 421-437.		3
567	The Cancer Genomics Resource List 2014. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 989-1008.	1.2	18
568	Pseudocarcinomatous hyperplasia associated with primary lymphoma in the urinary bladder: a case report. <i>Human Pathology</i> , 2015, 46, 1040-1044.	1.1	7
569	<i>BAP1</i> , <i>PBRM1</i> and <i>SETD2</i> in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 1201-1210.	1.5	78
570	Metabolic alterations in renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2015, 41, 767-776.	3.4	71
571	Modeling hepatitis B virus infection, immunopathology and therapy in mice. <i>Antiviral Research</i> , 2015, 121, 1-8.	1.9	26
572	Genitourinary small cell malignancies: prostate and bladder. <i>Future Oncology</i> , 2015, 11, 479-488.	1.1	16
573	Oncologic and quality-of-life outcomes with wide resection in robot-assisted laparoscopic radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 70.e9-70.e14.	0.8	4
574	Detection of BRAF Mutations on Direct Smears of Thyroid Fine-Needle Aspirates Through Cell Transfer Technique. <i>American Journal of Clinical Pathology</i> , 2015, 143, 500-504.	0.4	13
575	Incidental prostate cancer in Asian men: High prevalence of incidental prostatic adenocarcinoma in Chinese patients undergoing radical cystoprostatectomy for treatment of bladder cancer and selection of candidates for prostate-sparing cystectomy. <i>Prostate</i> , 2015, 75, 845-854.	1.2	15
576	Basal cell carcinoma of the prostate is an aggressive tumor with frequent loss of PTEN expression and overexpression of EGFR. <i>Human Pathology</i> , 2015, 46, 805-812.	1.1	34

#	ARTICLE	IF	CITATIONS
577	Calibration of a Novel, Laparoscopic, 12-mm, Ultrasound, Image-guided, High-intensity Focused Ultrasound Probe for Ablation of Renal Neoplasms. <i>Urology</i> , 2015, 85, 953-958.	0.5	3
578	Metanephric adenoma: the utility of immunohistochemical and cytogenetic analyses in differential diagnosis, including solid variant papillary renal cell carcinoma and epithelial-predominant nephroblastoma. <i>Modern Pathology</i> , 2015, 28, 1236-1248.	2.9	53
579	SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression. <i>Molecular Cell</i> , 2015, 59, 917-930.	4.5	172
580	Precision medicine in colorectal cancer: evolving genomic landscape and emerging consensus. <i>Future Oncology</i> , 2015, 11, 2711-2719.	1.1	5
581	Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation. <i>Molecular Cell</i> , 2015, 59, 904-916.	4.5	129
582	The origin of prostate metastases: emerging insights. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 765-773.	2.7	30
583	Does Squamous Differentiation Portend Worse Outcomes in Urothelial Bladder Cancer?. <i>Urology Practice</i> , 2015, 2, 335-342.	0.2	2
584	The changing reality of urothelial bladder cancer: should non-squamous variant histology be managed as a distinct clinical entity?. <i>BJU International</i> , 2015, 116, 236-240.	1.3	10
585	Lymph node metastases in patients with urothelial carcinoma variants: Influence of the specific variant on nodal histology. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 20.e23-20.e29.	0.8	20
586	Contemporary bladder cancer: Variant histology may be a significant driver of disease. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 18.e15-18.e20.	0.8	75
587	Increased androgen receptor gene copy number is associated with <i>TMPPRSS2-ERG</i> rearrangement in prostatic small cell carcinoma. <i>Molecular Carcinogenesis</i> , 2015, 54, 900-907.	1.3	28
588	Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy. <i>Modern Pathology</i> , 2015, 28, 480-486.	2.9	37
589	Rare Tumors and Tumor-like Conditions in Urological Pathology. , 2015, , .		3
590	Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer. <i>Modern Pathology</i> , 2015, 28, 612-630.	2.9	106
591	Renal cell carcinoma with angioleiomyoma-like stroma: clinicopathological, immunohistochemical, and molecular features supporting classification as a distinct entity. <i>Modern Pathology</i> , 2015, 28, 279-294.	2.9	50
592	MicroRNA and Transcription Factor Mediated Regulatory Network Analysis Reveals Critical Regulators and Regulatory Modules in Myocardial Infarction. <i>PLoS ONE</i> , 2015, 10, e0135339.	1.1	31
593	Morphologic and Molecular Backgrounds for Personalized Management of Genito-Urinary Cancers: An Overview. <i>Current Drug Targets</i> , 2015, 16, 96-102.	1.0	11
594	Molecular Foundations for Personalized Therapy in Prostate Cancer. <i>Current Drug Targets</i> , 2015, 16, 103-114.	1.0	26

#	ARTICLE	IF	CITATIONS
595	Oncotargets in Different Renal Cancer Subtypes. <i>Current Drug Targets</i> , 2015, 16, 125-135.	1.0	28
596	Bladder Cancer: Molecular Determinants of Personalized Therapy. <i>Current Drug Targets</i> , 2015, 16, 115-124.	1.0	18
597	Tumors and Tumor-Like Conditions of Urinary Bladder, Renal Pelvis, Ureter and Urethra. , 2015, , 63-194.		0
598	Testis and Paratesticular Structures. , 2015, , 311-371.		1
599	Small cell carcinoma of the prostate: molecular basis and clinical implications. <i>Histology and Histopathology</i> , 2015, 30, 413-24.	0.5	8
600	Pathological issues in biopsy specimens of men with prostate cancer eligible for active surveillance. <i>Archivio Italiano Di Urologia Andrologia</i> , 2014, 86, 314.	0.4	2
601	Immunotherapy of metastatic and autochthonous liver cancer with IL-15/IL-15R α fusion protein. <i>Oncolmmunology</i> , 2014, 3, e963409.	2.1	3
602	Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists. <i>Annals of Diagnostic Pathology</i> , 2014, 18, 333-342.	0.6	41
603	Utilization of cell-transferred cytologic smears in detection of EGFR and KRAS mutation on adenocarcinoma of lung. <i>Modern Pathology</i> , 2014, 27, 930-935.	2.9	18
604	Renal cell carcinoma with smooth muscle stroma lacks chromosome 3p and VHL alterations. <i>Modern Pathology</i> , 2014, 27, 765-774.	2.9	32
605	Molecular characteristics of urothelial neoplasms in children and young adults: a subset of tumors from young patients harbors chromosomal abnormalities but not FGFR3 or TP53 gene mutations. <i>Modern Pathology</i> , 2014, 27, 1540-1548.	2.9	19
606	The Application of Immunohistochemical Biomarkers in Urologic Surgical Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 1643-1665.	1.2	28
607	Re: Antibody-drug Conjugates Targeting Prostate-specific Membrane Antigen. <i>European Urology</i> , 2014, 66, 1190-1193.	0.9	5
608	Diagnostic criteria for ductal adenocarcinoma of the prostate: interobserver variability among 20 expert uropathologists. <i>Histopathology</i> , 2014, 65, 216-227.	1.6	40
609	Pediatric composite nodal marginal zone lymphoma and classical Hodgkin lymphoma. <i>Journal of Hematopathology</i> , 2014, 7, 171-175.	0.2	0
610	Does prostate acinar adenocarcinoma with Gleason Score 3 + 3 = 6 have the potential to metastasize?. <i>Diagnostic Pathology</i> , 2014, 9, 190.	0.9	10
611	Influence of Histologic Criteria and Confounding Factors in Staging Equivocal Cases for Microscopic Perivesical Tissue Invasion (pT3a). <i>American Journal of Surgical Pathology</i> , 2014, 38, 167-175.	2.1	16
612	Renal cell carcinoma with rhabdoid features and loss of INI1 expression in an individual without sickle cell trait. <i>Pathology</i> , 2014, 46, 653-655.	0.3	13

#	ARTICLE	IF	CITATIONS
613	Performance Evaluation Comparison of 3 Commercially Available PCR-based KRAS Mutation Testing Platforms. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2014, 22, 231-235.	0.6	10
614	Differential expression of <i>IMP3</i> between male and female mature teratomas—immunohistochemical evidence of malignant nature. <i>Histopathology</i> , 2014, 65, 483-489.	1.6	13
615	Renal Cell Carcinoma in Tuberous Sclerosis Complex. <i>American Journal of Surgical Pathology</i> , 2014, 38, 895-909.	2.1	203
616	Biomarkers in bladder cancer: Translational and clinical implications. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 73-111.	2.0	88
617	Clear cell renal cell carcinoma with intratumoral and nodal extramedullary megakaryopoiesis: a potential diagnostic pitfall. <i>Human Pathology</i> , 2014, 45, 1306-1309.	1.1	8
618	Clear Cell Renal Cell Carcinoma (ccRCC) with Hemangioblastoma-like Features: A Previously Unreported Pattern of ccRCC with Possible Clinical Significance. <i>European Urology</i> , 2014, 66, 806-810.	0.9	20
619	Plasmacytoid Bladder Cancer: Variant Histology With Aggressive Behavior and a New Mode of Invasion Along Fascial Planes. <i>Urology</i> , 2014, 83, 1112-1116.	0.5	62
620	Cytoplasmic OCT4 staining is a sensitive marker of neuroendocrine differentiation. <i>Human Pathology</i> , 2014, 45, 27-32.	1.1	20
621	Cholesteryl Ester Accumulation Induced by PTEN Loss and PI3K/AKT Activation Underlies Human Prostate Cancer Aggressiveness. <i>Cell Metabolism</i> , 2014, 19, 393-406.	7.2	671
622	Clear cell renal cell carcinoma with a syncytial-type multinucleated giant tumor cell component: implications for differential diagnosis. <i>Human Pathology</i> , 2014, 45, 735-744.	1.1	39
623	EGFR alterations and EML4-ALK rearrangement in primary adenocarcinoma of the urinary bladder. <i>Modern Pathology</i> , 2014, 27, 107-112.	2.9	12
624	Microcystic urothelial carcinoma: morphology, immunohistochemistry and clinical behaviour. <i>Histopathology</i> , 2014, 64, 872-879.	1.6	52
625	Neuroendocrine differentiation in prostate cancer: Novel morphological insights and future therapeutic perspectives. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 630-637.	3.3	38
626	Critical analysis of the 2010 TNM classification in patients with lymph node—positive bladder cancer: Influence of lymph node disease burden. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1003-1009.	0.8	9
627	Total submission of lymphadenectomy tissues removed during radical prostatectomy for prostate cancer: possible clinical significance of large-format histology. <i>Human Pathology</i> , 2014, 45, 2059-2062.	1.1	10
628	Plasmacytoid variant urothelial bladder cancer: Is it time to update the treatment paradigm? Contributed equally to manuscript. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 833-838.	0.8	54
629	Clinicopathological characteristics and outcome of nested carcinoma of the urinary bladder. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 465, 199-205.	1.4	69
630	Molecular subtyping of metastatic renal cell carcinoma: implications for targeted therapy. <i>Molecular Cancer</i> , 2014, 13, 39.	7.9	27

#	ARTICLE	IF	CITATIONS
631	Molecular pathology of malignant melanoma: changing the clinical practice paradigm toward a personalized approach. <i>Human Pathology</i> , 2014, 45, 1315-1326.	1.1	41
632	Seminal Vesicle Intraepithelial Neoplasia Versus Basal Cell Hyperplasia in a Seminal Vesicle. <i>European Urology</i> , 2014, 66, 623-627.	0.9	19
633	Recurrent papillary urothelial neoplasm of low malignant potential. Subtle architectural disorder detected by quantitative analysis in DAXX-immunostained tissue sections. <i>Human Pathology</i> , 2014, 45, 745-752.	1.1	6
634	Benign perivascular myoid cell tumor (myopericytoma) of the urinary tract: a report of 2 cases with an emphasis on differential diagnosis. <i>Human Pathology</i> , 2014, 45, 1115-1121.	1.1	28
635	A low grade PIN-like neoplasm of the transition zone immunohistochemically negative for basal cell markers: a possible example of low grade adenocarcinoma with stratified epithelium. <i>Pathology</i> , 2014, 46, 88-91.	0.3	7
636	qPCR Is a Sensitive and Rapid Method for Detection of Cytomegaloviral DNA in Formalin-fixed, Paraffin-embedded Biopsy Tissue. <i>Journal of Visualized Experiments</i> , 2014, , .	0.2	2
637	The Expression Patterns of p53 and p16 and an Analysis of a Possible Role of HPV in Primary Adenocarcinoma of the Urinary Bladder. <i>PLoS ONE</i> , 2014, 9, e95724.	1.1	18
638	Consolidation cystectomy after induction chemotherapy in node-positive urothelial bladder cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15520-e15520.	0.8	0
639	Immunohistochemical expression of prostate tumour overexpressed 1 (PTOV1) in atypical adenomatous hyperplasia (AAH) of the prostate. <i>Cellular Oncology (Dordrecht)</i> , 2013, 36, 37-42.	2.1	14
640	Central Prostate Pathology Review: Should It Be Mandatory?. <i>European Urology</i> , 2013, 64, 199-201.	0.9	23
641	Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry. <i>Human Pathology</i> , 2013, 44, 2227-2233.	1.1	45
642	Distinguishing primary adenocarcinoma of the urinary bladder from secondary involvement by colorectal adenocarcinoma: extended immunohistochemical profiles emphasizing novel markers. <i>Modern Pathology</i> , 2013, 26, 725-732.	2.9	88
643	Clonality Analysis and Tumor of Unknown Primary: Applications in Modern Oncology and Surgical Pathology. , 2013, , 129-180.		0
644	Laser Capture Microdissection in Molecular Diagnostics. , 2013, , 465-482.		4
645	Unique clinicopathologic and molecular characteristics of urinary bladder tumors in children and young adults. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 414-426.	0.8	34
646	Novel markers of squamous differentiation in the urinary bladder. <i>Human Pathology</i> , 2013, 44, 1989-1997.	1.1	37
647	Pathology of flat bladder lesions with emphasis on putative precursors. <i>Diagnostic Histopathology</i> , 2013, 19, 355-365.	0.2	4
648	Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations. <i>Future Oncology</i> , 2013, 9, 245-253.	1.1	12

#	ARTICLE	IF	CITATIONS
649	Re: Multilocular Cystic Renal Cell Carcinoma with Focus on Clinical and Pathobiological Aspects. <i>European Urology</i> , 2013, 63, 400-401.	0.9	14
650	Molecular Pathology of Urinary Bladder Cancer. , 2013, , 229-253.		1
651	Reply to JÃ©rÃ©me Verine's Letter to the Editor re: Rodolfo Montironi, Marina Scarpelli, Liang Cheng, et al. Immunoglobulin G4-related Disease in Genitourinary Organs: An Emerging Fibroinflammatory Entity Often Misdiagnosed Preoperatively as Cancer. <i>Eur Urol</i> . In press. http://dx.doi.org/10.1016/j.eururo.2012.11.056 . <i>European Urology</i> , 2013, 64, e53-e54.	0.9	0
652	Lymph node-positive bladder cancer: surgical, pathologic, molecular and prognostic aspects. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1281-1295.	1.1	13
653	Tubulocystic carcinoma of the kidney with poorly differentiated foci: a series of 3 cases with fluorescence in situ hybridization analysis. <i>Human Pathology</i> , 2013, 44, 1406-1411.	1.1	40
654	PAX8 expression in sporadic hemangioblastoma of the kidney supports a primary renal cell lineage: implications for differential diagnosis. <i>Human Pathology</i> , 2013, 44, 2247-2255.	1.1	35
655	The spectrum of histopathologic findings in vesical diverticulum: implications for pathogenesis and staging. <i>Human Pathology</i> , 2013, 44, 1223-1232.	1.1	47
656	Open vs. robotic-assisted radical prostatectomy: A single surgeon and pathologist comparison of pathologic and oncologic outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1043-1048.	0.8	23
657	Immunoglobulin G4-related Disease in Genitourinary Organs: An Emerging Fibroinflammatory Entity Often Misdiagnosed Preoperatively as Cancer. <i>European Urology</i> , 2013, 64, 865-872.	0.9	23
658	Paraganglion cells stain positively for <sc>OCT</sc>4: a potential pitfall in assessing retroperitoneal lymph node dissection specimens for germ cell tumour metastasis. <i>Histopathology</i> , 2013, 62, 360-363.	1.6	4
659	Renal cell carcinoma with clear cells, smooth muscle stroma, and negative for 3p deletion: a variant of renal angiomyoadenomatous tumour? A case report. <i>Histopathology</i> , 2013, 62, 522-524.	1.6	16
660	Tumors of the Urinary Bladder. , 2013, , 85-100.		0
661	Telomere shortening distinguishes inverted urothelial neoplasms. <i>Histopathology</i> , 2013, 62, 595-601.	1.6	20
662	Cathepsin K expression in a wide spectrum of perivascular epithelioid cell neoplasms (<sc>PEC</sc>omas): a clinicopathological study emphasizing extrarenal <sc>PEC</sc>omas. <i>Histopathology</i> , 2013, 62, 642-650.	1.6	77
663	Conceptual Evolution in Cancer Biology. , 2013, , 77-109.		1
664	Clear cell papillary renal cell carcinoma: differential diagnosis and extended immunohistochemical profile. <i>Modern Pathology</i> , 2013, 26, 697-708.	2.9	128
665	Clear Cell Papillary Renal Cell Carcinoma-like Tumors in Patients With Von Hippel-Lindau Disease Are Unrelated to Sporadic Clear Cell Papillary Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1131-1139.	2.1	70
666	Malignant Perivascular Epithelioid Cell Neoplasm (PEComa) of the Urinary Bladder With TFE3 Gene Rearrangement. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1619-1626.	2.1	73

#	ARTICLE	IF	CITATIONS
667	Atypical Adenomatous Hyperplasia of Prostate Lacks TMPRSS2-ERG Gene Fusion. American Journal of Surgical Pathology, 2013, 37, 1550-1554.	2.1	21
668	Somatostatin receptor expression in prostate carcinoma: the urological pathologist's role in the era of personalised medicine. Pathology, 2013, 45, 93-96.	0.3	4
669	Laser-assisted Microdissection in Translational Research. Applied Immunohistochemistry and Molecular Morphology, 2013, 21, 31-47.	0.6	63
670	Premalignancy of the testis and paratestis. Pathology, 2013, 45, 264-272.	0.3	17
671	Renal Tumors. American Journal of Surgical Pathology, 2013, 37, 1518-1531.	2.1	154
672	Urethral caruncle: a lesion related to IgG4-associated sclerosing disease?. Journal of Clinical Pathology, 2013, 66, 559-562.	1.0	18
673	PAX8 Mouse Monoclonal Antibody [BC12] Recognizes a Restricted Epitope and Is Highly Sensitive in Renal Cell and Ovarian Cancers But Does Not Cross-react With B Cells and Tumors of Pancreatic Origin. Applied Immunohistochemistry and Molecular Morphology, 2013, 21, 59-63.	0.6	48
674	Human Papillomavirus is Not an Etiologic Agent of Urothelial Inverted Papillomas. American Journal of Surgical Pathology, 2013, 37, 1223-1228.	2.1	22
675	Cystic partially regressed clear cell renal cell carcinoma: a potential mimic of multilocular cystic renal cell carcinoma. Histopathology, 2013, 63, 767-779.	1.6	29
676	Combined handling of prostate base/bladder neck and seminal vesicles in radical prostatectomy specimens: our approach with the whole mount technique. Histopathology, 2013, 63, 431-435.	1.6	8
677	Cytoplasmic Staining of OCT4 Is a Highly Sensitive Marker of Adrenal Medullary-derived Tissue. American Journal of Surgical Pathology, 2013, 37, 727-733.	2.1	16
678	Evidence Supporting the Existence of Benign Teratomas of the Postpubertal Testis. American Journal of Surgical Pathology, 2013, 37, 827-835.	2.1	70
679	TFE3 Break-apart FISH Has a Higher Sensitivity for Xp11.2 Translocation-associated Renal Cell Carcinoma Compared With TFE3 or Cathepsin K Immunohistochemical Staining Alone. American Journal of Surgical Pathology, 2013, 37, 804-815.	2.1	158
680	Molecular Pathology of Kidney Tumors. , 2013, , 171-212.		3
681	Urothelial dysplasia of the bladder: diagnostic features and clinical significance. Analytical and Quantitative Cytopathology and Histopathology, 2013, 35, 121-9.	0.2	7
682	From "No Pay, No Play" or From "Defensive or Passive Pathology" to "Active, Clinically Oriented Pathology". Archives of Pathology and Laboratory Medicine, 2012, 136, 1474-1475.	1.2	1
683	p16 expression is not associated with human papillomavirus in urinary bladder squamous cell carcinoma. Modern Pathology, 2012, 25, 1526-1533.	2.9	73
684	Molecular genetic evidence supporting the neoplastic nature of fibrous stroma in testicular teratoma. Modern Pathology, 2012, 25, 1432-1438.	2.9	25

#	ARTICLE	IF	CITATIONS
685	Anatomic, morphologic and genetic heterogeneity of prostate cancer: implications for clinical practice. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1371-1374.	1.1	20
686	Emerging Critical Role of Molecular Testing in Diagnostic Genitourinary Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 372-390.	1.2	42
687	Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway. <i>Endocrine-Related Cancer</i> , 2012, 19, 321-331.	1.6	79
688	Polysomy of Chromosomes 1 and/or 19 Is Common and Associated With Less Favorable Clinical Outcome in Oligodendrogliomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2012, 71, 618-624.	0.9	37
689	Signet Ring Cell Carcinoma of the Testis. <i>American Journal of Surgical Pathology</i> , 2012, 36, 311-315.	2.1	10
690	Multilocular Cystic Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1425-1433.	2.1	75
691	Renal Cell Carcinomas With t(6;11)(p21;q12). <i>American Journal of Surgical Pathology</i> , 2012, 36, 1327-1338.	2.1	88
692	Molecular Genetic Evidence Supporting the Origin of Somatic-type Malignancy and Teratoma From the Same Progenitor Cell. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1849-1856.	2.1	58
693	Precursors of prostate cancer. <i>Histopathology</i> , 2012, 60, 4-27.	1.6	86
694	Do Not Misinterpret Intraductal Carcinoma of the Prostate as High-grade Prostatic Intraepithelial Neoplasia!. <i>European Urology</i> , 2012, 62, 518-522.	0.9	26
695	PAX8 is expressed in the majority of renal epithelial neoplasms: an immunohistochemical study of 223 cases using a mouse monoclonal antibody. <i>Journal of Clinical Pathology</i> , 2012, 65, 254-256.	1.0	37
696	Urethral caruncle: clinicopathologic features of 41 cases. <i>Human Pathology</i> , 2012, 43, 1400-1404.	1.1	49
697	Histologic grading of urothelial carcinoma: a reappraisal. <i>Human Pathology</i> , 2012, 43, 2097-2108.	1.1	78
698	Evidence for clonal fibroblast proliferation and autoimmune process in idiopathic retroperitoneal fibrosis. <i>Human Pathology</i> , 2012, 43, 1875-1880.	1.1	15
699	Molecular pathology of lung cancer: key to personalized medicine. <i>Modern Pathology</i> , 2012, 25, 347-369.	2.9	215
700	Staging of prostate cancer. <i>Histopathology</i> , 2012, 60, 87-117.	1.6	114
701	Prostate cancer: towards the standardization and synthesis of morphology, genetics, and prognosis. <i>Histopathology</i> , 2012, 60, 1-3.	1.6	4
702	Re: "No Pay, No Play": The End of Professional Ethics in Pathology?. <i>European Urology</i> , 2012, 61, 424-425.	0.9	1

#	ARTICLE	IF	CITATIONS
703	<i>KRAS</i> mutation is present in a small subset of primary urinary bladder adenocarcinomas. <i>Histopathology</i> , 2012, 61, 1036-1042.	1.6	23
704	Unclassified renal cell carcinoma: a report of 56 cases. <i>BJU International</i> , 2012, 110, 786-793.	1.3	38
705	Lymphocytic vasculitis of the prostate transition zone. <i>BJU International</i> , 2012, 110, 1775-1780.	1.3	7
706	Current treatment of metastatic bladder cancer and future directions. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1851-1862.	1.1	25
707	Lymphadenectomy in Urologic Oncology: Pathologic Considerations. <i>Urologic Clinics of North America</i> , 2011, 38, 483-495.	0.8	8
708	The clinical and therapeutic implications of cancer stem cell biology. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1133-1145.	1.1	24
709	The landscape of <i>EGFR</i> pathways and personalized management of non-small-cell lung cancer. <i>Future Oncology</i> , 2011, 7, 519-541.	1.1	47
710	Prostate. , 2011, , 1581-1616.		0
711	Perivascular Epithelioid Cell Tumor of the Bladder. <i>Journal of Urology</i> , 2011, 185, 1473-1474.	0.2	6
712	Bladder cancer: translating molecular genetic insights into clinical practice. <i>Human Pathology</i> , 2011, 42, 455-481.	1.1	173
713	Flat urothelial carcinoma in situ of the bladder with glandular differentiation. <i>Human Pathology</i> , 2011, 42, 1653-1659.	1.1	38
714	Lymph node-positive prostate cancer: current issues, emerging technology and impact on clinical outcome. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1457-1469.	1.1	11
715	Tumor Focality Does Not Predict Biochemical Recurrence After Radical Prostatectomy in Men With Clinically Localized Prostate Cancer. <i>Journal of Urology</i> , 2011, 186, 506-510.	0.2	19
716	Proteomic studies of Anaplasia in Wilms Tumor. <i>Proteomics Insights</i> , 2011, 4, PRI.S7466.	2.0	3
717	Mixed Epithelial and Stromal Tumors of the Kidney. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1114-1122.	2.1	31
718	Expression of PAX8 in Normal and Neoplastic Tissues. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2011, 19, 293-299.	0.6	197
719	Lymphoepithelioma-like Carcinoma of the Urinary Bladder. <i>American Journal of Surgical Pathology</i> , 2011, 35, 474-483.	2.1	88
720	Sarcomatoid Carcinoma of the Urinary Bladder. <i>American Journal of Surgical Pathology</i> , 2011, 35, e34-e46.	2.1	112

#	ARTICLE	IF	CITATIONS
721	Pathological characterization of unifocal prostate cancers in whole-mount radical prostatectomy specimens. <i>BJU International</i> , 2011, 107, 1587-1591.	1.3	22
722	Urothelial lesions with inverted growth patterns: histogenesis, molecular genetic findings, differential diagnosis and clinical management. <i>BJU International</i> , 2011, 107, 532-537.	1.3	42
723	Glandular lesions of the urinary bladder: clinical significance and differential diagnosis. <i>Histopathology</i> , 2011, 58, 811-834.	1.6	59
724	How much do you know about benign, preneoplastic, non-invasive and invasive neoplastic lesions of the urinary bladder classified according to the 2004 WHO scheme?. <i>Diagnostic Pathology</i> , 2011, 6, 31.	0.9	9
725	Inverted (Endophytic) Noninvasive Lesions and Neoplasms of the Urothelium: The Cinderella Group Has Yet to Be Fully Exploited. <i>European Urology</i> , 2011, 59, 225-230.	0.9	23
726	The Importance of Interaction Between Urologists and Pathologists in Incidental Prostate Cancer Management. <i>European Urology</i> , 2011, 60, 75-77.	0.9	9
727	<i>Schistosoma japonicum</i> : Treatment of different developmental stages in mice with long-acting praziquantel implants. <i>Experimental Parasitology</i> , 2011, 129, 254-259.	0.5	3
728	Squamous cysts arising from segmental renal dysplasia. <i>Pediatric Nephrology</i> , 2011, 26, 1893-1896.	0.9	3
729	Elevated expression of cancer-associated proliferating cell nuclear antigen in high-grade prostatic intraepithelial neoplasia and prostate cancer. <i>Prostate</i> , 2011, 71, 748-754.	1.2	22
730	Is atypical adenomatous hyperplasia of the prostate a precursor lesion?. <i>Prostate</i> , 2011, 71, 1746-1751.	1.2	25
731	<i>KIT</i> gene mutation and amplification in dysgerminoma of the ovary. <i>Cancer</i> , 2011, 117, 2096-2103.	2.0	85
732	Pleomorphic xanthoastrocytoma and oligodendroglioma: collision of 2 morphologically and genetically distinct anaplastic components. <i>Journal of Neurosurgery</i> , 2011, 114, 1648-1653.	0.9	11
733	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins. <i>Modern Pathology</i> , 2011, 24, 48-57.	2.9	239
734	Polo-like Kinase 1 Facilitates Loss of Pten Tumor Suppressor-induced Prostate Cancer Formation. <i>Journal of Biological Chemistry</i> , 2011, 286, 35795-35800.	1.6	57
735	ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. <i>Modern Pathology</i> , 2011, 24, 1120-1127.	2.9	130
736	Tumors of the Kidney. , 2011, , 1487-1514.		1
737	Renal Pelvis, Ureter, and Urethra. , 2011, , 1567-1579.		0
738	Urinary Bladder. , 2011, , 1515-1565.		0

#	ARTICLE	IF	CITATIONS
739	Many facets of chromosome 3p cytogenetic findings in clear cell renal carcinoma: the need for agreement in assessment FISH analysis to avoid diagnostic errors. <i>Histology and Histopathology</i> , 2011, 26, 1207-13.	0.5	16
740	Radical prostatectomy as initial monotherapy for patients with pathologically confirmed high-grade prostate cancer. <i>BJU International</i> , 2010, 105, 1372-1376.	1.3	8
741	Urothelial Carcinoma of the Bladder, Lipid Cell Variant: Clinicopathologic Findings and LOH Analysis. <i>American Journal of Surgical Pathology</i> , 2010, 34, 371-376.	2.1	62
742	Interobserver Reproducibility in the Diagnosis of Invasive Micropapillary Carcinoma of the Urinary Tract Among Urologic Pathologists. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1367-1376.	2.1	111
743	Clear Cell Tubulopapillary Renal Cell Carcinoma: A Study of 36 Distinctive Low-grade Epithelial Tumors of the Kidney. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1608-1621.	2.1	185
744	Multivariate statistical differentiation of renal cell carcinomas based on lipidomic analysis by ambient ionization imaging mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 398, 2969-2978.	1.9	137
745	Cyclin D3 gene amplification in bladder carcinoma in situ. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2010, 457, 555-561.	1.4	17
746	Re: Peripheral Zone Prostate Cancers: Location and Intraprostatic Patterns of Spread at Histopathology. <i>European Urology</i> , 2010, 58, 180-182.	0.9	5
747	Prognostic and Therapeutic Impact of the Histopathologic Definition of Parenchymal Epithelial Renal Tumors. <i>European Urology</i> , 2010, 58, 655-668.	0.9	84
748	Clonal origin of multifocal hepatocellular carcinoma. <i>Cancer</i> , 2010, 116, 4078-4085.	2.0	17
749	A Highly Selective Nitroaldol Reaction Catalyzed by Cu(II)-Bisimidazoline. <i>Chemistry - A European Journal</i> , 2010, 16, 6761-6765.	1.7	71
750	pT0 prostate cancer after radical prostatectomy. <i>Journal of Surgical Oncology</i> , 2010, 102, 331-333.	0.8	17
751	In vitro and in vivo evaluation of praziquantel loaded implants based on PEG/PCL blends. <i>International Journal of Pharmaceutics</i> , 2010, 387, 129-138.	2.6	70
752	Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder: The state of the art. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 76, 112-126.	2.0	43
753	Histopathological findings after treatment of prostate cancer using high-intensity focused ultrasound (HIFU). <i>Prostate</i> , 2010, 70, 1196-1200.	1.2	42
754	Atypical sclerosing adenosis of the prostate: a rare mimic of adenocarcinoma. <i>Histopathology</i> , 2010, 56, 627-631.	1.6	26
755	Genetic profiles in renal tumors. <i>International Journal of Urology</i> , 2010, 17, 6-19.	0.5	10
756	Diagnostic Utility of Novel Stem Cell Markers SALL4, OCT4, NANOG, SOX2, UTF1, and TCL1 in Primary Mediastinal Germ Cell Tumors. <i>American Journal of Surgical Pathology</i> , 2010, 34, 697-706.	2.1	128

#	ARTICLE	IF	CITATIONS
757	Renal Cell Neoplasms of Oncocytosis Have Distinct Morphologic, Immunohistochemical, and Cytogenetic Profiles. <i>American Journal of Surgical Pathology</i> , 2010, 34, 620-626.	2.1	58
758	Clonality and TP53 Mutation Analysis of Focal Nodular Hyperplasia of the Liver. <i>American Journal of Clinical Pathology</i> , 2010, 134, 65-70.	0.4	8
759	Does the Size Matter?. <i>American Journal of Clinical Pathology</i> , 2010, 133, 662-668.	0.4	13
760	Primitive neuroectodermal tumors in patients with testicular germ cell tumors usually resemble pediatric-type central nervous system embryonal neoplasms and lack chromosome 22 rearrangements. <i>Modern Pathology</i> , 2010, 23, 972-980.	2.9	60
761	Understanding the molecular genetics of renal cell neoplasia: implications for diagnosis, prognosis and therapy. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 843-864.	1.1	34
762	Large cell undifferentiated carcinoma of the urinary bladder. <i>Pathology</i> , 2010, 42, 364-368.	0.3	26
763	Multilocular cystic renal cell carcinoma is a subtype of clear cell renal cell carcinoma. <i>Modern Pathology</i> , 2010, 23, 931-936.	2.9	101
764	Neural Neoplasms of the Bladder. <i>Journal of Urology</i> , 2010, 184, 1492-1493.	0.2	2
765	Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features. <i>Human Pathology</i> , 2010, 41, 155-162.	1.1	86
766	Clonal evidence for the progression of a testicular germ cell tumor to angiosarcoma. <i>Human Pathology</i> , 2010, 41, 139-144.	1.1	15
767	Morphologic, immunohistochemical, and fluorescence in situ hybridization study of ovarian embryonal carcinoma with comparison to solid variant of yolk sac tumor and immature teratoma. <i>Human Pathology</i> , 2010, 41, 716-723.	1.1	47
768	Invasive micropapillary urothelial carcinoma of the bladder. <i>Human Pathology</i> , 2010, 41, 1159-1164.	1.1	73
769	Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. <i>Human Pathology</i> , 2010, 41, 781-793.	1.1	243
770	The origins of urothelial carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 865-880.	1.1	72
771	Clinical Utility of Immunohistochemistry in the Diagnoses of Urinary Bladder Neoplasia. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2010, 18, 401-410.	0.6	54
772	Small cell carcinoma of the urinary bladder. <i>Histology and Histopathology</i> , 2010, 25, 217-21.	0.5	33
773	The Pathology of Prostate Cancer. , 2010, , 45-83.		2
774	Contemporary approaches for processing and handling of radical prostatectomy specimens. <i>Histology and Histopathology</i> , 2010, 25, 259-65.	0.5	8

#	ARTICLE	IF	CITATIONS
775	Is Incidentally Detected Prostate Cancer in Patients Undergoing Radical Cystoprostatectomy Clinically Significant?. American Journal of Clinical Pathology, 2009, 131, 279-283.	0.4	55
776	Evidence for Common Clonal Origin of Multifocal Lung Cancers. Journal of the National Cancer Institute, 2009, 101, 560-570.	3.0	142
777	Molecular determinants of tumor recurrence in the urinary bladder. Future Oncology, 2009, 5, 843-857.	1.1	45
778	Pathology of the prostate in radical cystectomy specimens: A critical review. Surgical Oncology, 2009, 18, 73-84.	0.8	22
779	Editorial Comment on: Prevalence of a Tertiary Gleason Grade and Its Impact on Adverse Histopathologic Parameters in a Contemporary Radical Prostatectomy Series. European Urology, 2009, 55, 402.	0.9	1
780	Critical Evaluation of the Prostate from Cystoprostatectomies for Bladder Cancer: Insights from a Complete Sampling with the Whole Mount Technique. European Urology, 2009, 55, 1305-1309.	0.9	27
781	Solitary Fibrous Tumour of the Prostate Identified on Needle Biopsy. European Urology, 2009, 56, 564-567.	0.9	24
782	Stage pT0 in Radical Prostatectomy with No Residual Carcinoma and with a Previous Positive Biopsy Conveys a Wrong Message to Clinicians and Patients: Why Is Cancer Not Present in the Radical Prostatectomy Specimen?. European Urology, 2009, 56, 272-274.	0.9	16
783	Joint Appraisal of the Radical Prostatectomy Specimen by the Urologist and the Uropathologist: Together, We Can Do It Better. European Urology, 2009, 56, 951-955.	0.9	23
784	Decision support systems for morphology-based diagnosis and prognosis of prostate neoplasms. Cancer, 2009, 115, 3068-3077.	2.0	10
785	Urothelial carcinoma following augmentation cystoplasty: an aggressive variant with distinct clinicopathological characteristics and molecular genetic alterations. Histopathology, 2009, 55, 161-173.	1.6	40
786	Epidermal growth factor receptor protein expression and gene amplification in the chemorefractory metastatic embryonal carcinoma. Modern Pathology, 2009, 22, 7-12.	2.9	23
787	TP53 mutational analysis supports monoclonal origin of biphasic sarcomatoid urothelial carcinoma (carcinosarcoma) of the urinary bladder. Modern Pathology, 2009, 22, 113-118.	2.9	68
788	Staging and reporting of urothelial carcinoma of the urinary bladder. Modern Pathology, 2009, 22, S70-S95.	2.9	166
789	FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations. Modern Pathology, 2009, 22, 627-632.	2.9	47
790	2009 update on the classification of renal epithelial tumors in adults. International Journal of Urology, 2009, 16, 432-443.	0.5	207
791	PATHOLOGICAL DEFINITION AND DIFFICULTIES IN ASSESSING POSITIVE MARGINS IN RADICAL PROSTATECTOMY SPECIMENS. BJU International, 2009, 103, 286-288.	1.3	14
792	Urothelial and incidental prostate carcinoma in prostates from cystoprostatectomies for bladder cancer: is there a relationship between urothelial and prostate cancer?. BJU International, 2009, 103, 1058-1063.	1.3	29

#	ARTICLE	IF	CITATIONS
793	Neuroendocrine tumours of the urinary system and male genital organs: clinical significance. <i>BJU International</i> , 2009, 103, 1464-1470.	1.3	94
794	Secondary neoplasms of the urinary system and male genital organs. <i>BJU International</i> , 2009, 104, 770-776.	1.3	72
795	Characterization and in vitro release of praziquantel from poly(ϵ -caprolactone) implants. <i>International Journal of Pharmaceutics</i> , 2009, 377, 112-119.	2.6	56
796	Sarcomatoid carcinoma of the upper urinary tract: clinical outcome and molecular characterization. <i>Human Pathology</i> , 2009, 40, 211-217.	1.1	30
797	CD44 expression is a feature of prostatic small cell Carcinoma and Distinguishes it from its Mimickers. <i>Human Pathology</i> , 2009, 40, 252-258.	1.1	71
798	Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. <i>Human Pathology</i> , 2009, 40, 10-29.	1.1	108
799	Lymphoepithelioma-like carcinoma of the prostate. <i>Human Pathology</i> , 2009, 40, 982-987.	1.1	25
800	Plasmacytoid urothelial carcinoma of the bladder. <i>Human Pathology</i> , 2009, 40, 1023-1028.	1.1	103
801	Pleomorphic giant cell carcinoma of the urinary bladder. <i>Human Pathology</i> , 2009, 40, 1461-1466.	1.1	50
802	2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms: Inherent Problems and Clinical Reflections. <i>European Urology Supplements</i> , 2009, 8, 453-457.	0.1	21
803	Evidence for Transformation of Fibroadenoma of the Breast to Malignant Phyllodes Tumor. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2009, 17, 345-350.	0.6	34
804	Implications of Cancer Stem Cells for Cancer Therapy. , 2009, , 255-262.		4
805	Proteomicâ€based approach for biomarkers discovery in early detection of invasive urothelial carcinoma. <i>Proteomics - Clinical Applications</i> , 2008, 2, 78-89.	0.8	13
806	Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: A fluorescence in situ hybridization and immunohistochemical analysis. <i>Prostate</i> , 2008, 68, 919-923.	1.2	29
807	Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur. <i>Cancer</i> , 2008, 112, 636-644.	2.0	41
808	Interphase cytogenetic analysis with centromeric probes for chromosomes 1, 2, 6, 10, and 17 in 11 tumors from a patient with bilateral renal oncocytosis. <i>Modern Pathology</i> , 2008, 21, 498-504.	2.9	25
809	Loss of chromosome 9p is an independent prognostic factor in patients with clear cell renal cell carcinoma. <i>Modern Pathology</i> , 2008, 21, 1-6.	2.9	97
810	Hypermethylation of tumor-suppressor gene CpG islands in small-cell carcinoma of the urinary bladder. <i>Modern Pathology</i> , 2008, 21, 355-362.	2.9	33

#	ARTICLE	IF	CITATIONS
811	Pathological variants of invasive bladder cancer according to their suggested clinical significance. <i>BJU International</i> , 2008, 101, 275-281.	1.3	47
812	Rare and unusual histological variants of prostatic carcinoma: clinical significance. <i>BJU International</i> , 2008, 102, 1369-1374.	1.3	56
813	Editorial Comment on: Prediction of Progression of Non-Muscle-Invasive Bladder Cancer by WHO 1973 and 2004 Grading and by FGFR3 Mutation Status: A Prospective Study. <i>European Urology</i> , 2008, 54, 843-844.	0.9	2
814	Inflammatory Myofibroblastic Tumors of the Genitourinary Tract—Single Entity or Continuum?. <i>Journal of Urology</i> , 2008, 180, 1235-1240.	0.2	81
815	Papillary renal cell carcinoma with oncocytic cells and nonoverlapping low grade nuclei: expanding the morphologic spectrum with emphasis on clinicopathologic, immunohistochemical and molecular features. <i>Human Pathology</i> , 2008, 39, 96-101.	1.1	100
816	Lymphatic vessel density in radical prostatectomy specimens. <i>Human Pathology</i> , 2008, 39, 610-615.	1.1	23
817	Cytokeratin (AE1/AE3) in addition to Î±-methylacyl coenzyme A racemase (P504S), 34-beta-E12, and p63 stains in evaluation of surgical specimens after hormonal therapy for prostatic adenocarcinoma—reply. <i>Human Pathology</i> , 2008, 39, 305-306.	1.1	0
818	Ureteral endometriosis: clinicopathological and immunohistochemical study of 7 cases. <i>Human Pathology</i> , 2008, 39, 954-959.	1.1	59
819	Expression of RNA-binding protein IMP3 (KOC) in benign urothelium and urothelial tumors. <i>Human Pathology</i> , 2008, 39, 1205-1211.	1.1	34
820	Targeted therapies and biological modifiers in urologic tumors: pathobiology and clinical implications. <i>Seminars in Diagnostic Pathology</i> , 2008, 25, 232-244.	1.0	9
821	Germ Cell Origin of Testicular Carcinoid Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 1393-1396.	3.2	49
822	Histogenesis of Clear Cell Adenocarcinoma in the Urinary Tract: Evidence of Urothelial Origin. <i>Clinical Cancer Research</i> , 2008, 14, 1947-1955.	3.2	78
823	Ionizing Radiation Induces Prostate Cancer Neuroendocrine Differentiation through Interplay of CREB and ATF2: Implications for Disease Progression. <i>Cancer Research</i> , 2008, 68, 9663-9670.	0.4	100
824	Anti-LOX-1 therapy in rats with diabetes and dyslipidemia: ablation of renal vascular and epithelial manifestations. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 294, F110-F119.	1.3	42
825	Evidence for Polyclonal Origin of Multifocal Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 8087-8093.	3.2	43
826	Renal Cell Carcinomas With Papillary Architecture and Clear Cell Components. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1780-1786.	2.1	98
827	Primary Mediastinal Seminoma: A Comprehensive Assessment Integrated With Histology, Immunohistochemistry, and Fluorescence In Situ Hybridization for Chromosome 12p Abnormalities in 23 Cases. <i>American Journal of Surgical Pathology</i> , 2008, 32, 146-155.	2.1	71
828	Grade 1 Urothelial Carcinoma Versus PUNLMP. , 2008, 13, 144-148.		1

#	ARTICLE	IF	CITATIONS
829	Clear Cell Papillary Renal Cell Carcinoma. American Journal of Surgical Pathology, 2008, 32, 1239-1245.	2.1	252
830	Neoplasms of the kidney. , 2008, , 76-171.		5
831	Neoplasms of the urinary bladder. , 2008, , 258-351.		25
832	Renal pelvis and ureter. , 2008, , 172-193.		2
833	Clonality Analysis in Modern Oncology and Surgical Pathology. , 2008, , 261-301.		0
834	Laser Capture Microdissection. , 2008, , 141-154.		0
835	Metastasizing breast carcinoma to the brain: a clinicopathologic and immunohistochemical study of 14 matched pairs.. FASEB Journal, 2008, 22, 706.24.	0.2	0
836	Laser capture microdissection in the genomic and proteomic era: targeting the genetic basis of cancer. International Journal of Clinical and Experimental Pathology, 2008, 1, 475-88.	0.5	35
837	Eosinophilic metaplasia of the prostate: a newly described lesion distinct from other eosinophilic changes in prostatic epithelium. , 2008, 30, 226-30.		0
838	Overdiagnosis of bladder carcinoma. , 2008, 30, 261-4.		1
839	Morphological and molecular profiles and pathways in bladder neoplasms. Anticancer Research, 2008, 28, 2893-900.	0.5	12
840	Pure cartilaginous teratoma of the testis: an immunohistochemistry and fluorescence in situ hybridisation study. Journal of Clinical Pathology, 2007, 60, 1166-1168.	1.0	3
841	Î±-Methylacyl Coenzyme A Racemase, Ki-67, and Topoisomerase IIÎ± in Cystoprostatectomies With Incidental Prostate Cancer. American Journal of Clinical Pathology, 2007, 128, 657-664.	0.4	25
842	Epidermal Growth Factor Receptor Protein Expression and Gene Amplification in Small Cell Carcinoma of the Urinary Bladder. Clinical Cancer Research, 2007, 13, 953-957.	3.2	76
843	Telomere Shortening and Chromosomal Abnormalities in Intestinal Metaplasia of the Urinary Bladder. Clinical Cancer Research, 2007, 13, 6232-6236.	3.2	64
844	Molecular Genetic Evidence of an Independent Origin of Serous Low Malignant Potential Implants and Lymph Node Inclusions. International Journal of Gynecological Pathology, 2007, 26, 387-394.	0.9	28
845	Genetically Heterogeneous and Clonally Unrelated Metastases May Arise in Patients With Cutaneous Melanoma. American Journal of Surgical Pathology, 2007, 31, 1029-1037.	2.1	54
846	Loss of Heterozygosity Analysis Identifies Genetic Abnormalities in Mycosis Fungoides and Specific Loci Associated With Disease Progression. American Journal of Surgical Pathology, 2007, 31, 1552-1556.	2.1	22

#	ARTICLE	IF	CITATIONS
847	Positive-block Ratio in Radical Prostatectomy Specimens is an Independent Predictor of Prostate-specific Antigen Recurrence. <i>American Journal of Surgical Pathology</i> , 2007, 31, 877-881.	2.1	25
848	Expression of OCT4 Transcription Factor in Cutaneous Neoplasia. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2007, 15, 359-362.	0.6	9
849	Urothelial Carcinoma With an Inverted Growth Pattern Can be Distinguished From Inverted Papilloma by Fluorescence In Situ Hybridization, Immunohistochemistry, and Morphologic Analysis. <i>American Journal of Surgical Pathology</i> , 2007, 31, 1861-1867.	2.1	82
850	Molecular Genetic Evidence Supporting the Neoplastic Nature of the Leydig Cell Component of Ovarian Sertoli-Leydig Cell Tumors. <i>International Journal of Gynecological Pathology</i> , 2007, 26, 368-374.	0.9	15
851	Carcinomas of Ovary and Lung With Clear Cell Features. <i>International Journal of Gynecological Pathology</i> , 2007, 26, 134-140.	0.9	18
852	Radial Distance of Extraprostatic Extension Measured by Ocular Micrometer is an Independent Predictor of Prostate-specific Antigen Recurrence. <i>American Journal of Surgical Pathology</i> , 2007, 31, 311-318.	2.1	73
853	Small Cell Carcinoma of the Urinary Bladder—Histogenesis, Genetics, Diagnosis, Biomarkers, Treatment, and Prognosis. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2007, 15, 8-18.	0.6	54
854	Mechanisms of Disease: high-grade prostatic intraepithelial neoplasia and other proposed preneoplastic lesions in the prostate. <i>Nature Reviews Urology</i> , 2007, 4, 321-332.	1.4	75
855	Î±-methylacyl-CoA racemase (P504S)/34Î²E12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy. <i>Human Pathology</i> , 2007, 38, 332-341.	1.1	39
856	The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens. <i>Human Pathology</i> , 2007, 38, 1207-1211.	1.1	69
857	Soft tissue tumors of the urinary bladder. <i>Human Pathology</i> , 2007, 38, 963-977.	1.1	79
858	Soft tissue tumors of the urinary bladder, part I: myofibroblastic proliferations, benign neoplasms, and tumors of uncertain malignant potential. <i>Human Pathology</i> , 2007, 38, 807-823.	1.1	93
859	Radical prostatectomy specimen processing: A critical appraisal of sampling methods. <i>Current Diagnostic Pathology</i> , 2007, 13, 490-498.	0.4	5
860	Does the Presence of Extranodal Extension in Pathological Stage B1 Nonseminomatous Germ Cell Tumor Necessitate Adjuvant Chemotherapy?. <i>Journal of Urology</i> , 2007, 177, 944-946.	0.2	23
861	Phase I/II Trial of High Intensity Focused Ultrasound for the Treatment of Previously Untreated Localized Prostate Cancer. <i>Journal of Urology</i> , 2007, 178, 2366-2371.	0.2	36
862	Percentage of Gleason pattern 4 and 5 predicts survival after radical prostatectomy. <i>Cancer</i> , 2007, 110, 1967-1972.	2.0	63
863	Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit, and androgen receptor in phyllodes tumor of the prostate. <i>Modern Pathology</i> , 2007, 20, 175-182.	2.9	36
864	Chromosomal gains in the sarcomatoid transformation of chromophobe renal cell carcinoma. <i>Modern Pathology</i> , 2007, 20, 303-309.	2.9	76

#	ARTICLE	IF	CITATIONS
865	The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders. <i>Modern Pathology</i> , 2007, 20, 929-935.	2.9	44
866	Clonal relationships between epidermotropic metastatic melanomas and their primary lesions: a loss of heterozygosity and X-chromosome inactivation-based analysis. <i>Modern Pathology</i> , 2007, 20, 821-827.	2.9	20
867	Histologic Grading of Noninvasive Papillary Urothelial Neoplasms. <i>European Urology</i> , 2007, 51, 889-898.	0.9	131
868	Classical pathology versus molecular pathology in renal cell carcinoma. <i>Current Urology Reports</i> , 2007, 8, 5-11.	1.0	12
869	Neoplasms of the Kidney. , 2007, , 281-340.		1
870	Tertiary Gleason Pattern 5 is a Powerful Predictor of Biochemical Relapse in Patients With Gleason Score 7 Prostatic Adenocarcinoma. <i>Journal of Urology</i> , 2006, 175, 1695-1699.	0.2	94
871	Papillary Urothelial Neoplasm of Low Malignant Potential: Evolving Terminology and Concepts. <i>Journal of Urology</i> , 2006, 175, 1995-2003.	0.2	82
872	Implications of cancer stem cells in the treatment of cancer. <i>Future Oncology</i> , 2006, 2, 723-731.	1.1	36
873	OCT4 is superior to CD30 in the diagnosis of metastatic embryonal carcinomas after chemotherapy. <i>Human Pathology</i> , 2006, 37, 662-667.	1.1	63
874	Cytokeratin and CD30 expression in dysgerminoma. <i>Human Pathology</i> , 2006, 37, 1015-1021.	1.1	40
875	Histologic variants of urothelial carcinoma: differential diagnosis and clinical implications. <i>Human Pathology</i> , 2006, 37, 1371-1388.	1.1	201
876	Invasion of fat justifies assignment of stage pT3a in prostatic adenocarcinoma. <i>Pathology</i> , 2006, 38, 309-311.	0.3	34
877	Small Cell Carcinoma of the Prostate: An Immunohistochemical Study. <i>American Journal of Surgical Pathology</i> , 2006, 30, 705-712.	2.1	190
878	Retroperitoneal Seminoma in Limited Biopsies: Morphologic Criteria and Immunohistochemical Findings in 30 Cases. <i>American Journal of Surgical Pathology</i> , 2006, 30, 766-773.	2.1	23
879	Adrenal Myelolipomas Show Nonrandom X-chromosome Inactivation in Hematopoietic Elements and Fat: Support for a Clonal Origin of Myelolipomas. <i>American Journal of Surgical Pathology</i> , 2006, 30, 838-843.	2.1	93
880	Screening for Intratubular Germ Cell Neoplasia of the Testis Using OCT4 Immunohistochemistry. <i>American Journal of Surgical Pathology</i> , 2006, 30, 1427-1431.	2.1	19
881	Is prostate-specific antigen (PSA) density better than the preoperative PSA level in predicting early biochemical recurrence of prostate cancer after radical prostatectomy?. <i>BJU International</i> , 2006, 97, 480-484.	1.3	19
882	Renal mucinous tubular and spindle carcinoma lacks the gains of chromosomes 7 and 17 and losses of chromosome Y that are prevalent in papillary renal cell carcinoma. <i>Modern Pathology</i> , 2006, 19, 488-493.	2.9	126

#	ARTICLE	IF	CITATIONS
883	Chromosome 12p abnormalities in dysgerminoma of the ovary: a FISH analysis. <i>Modern Pathology</i> , 2006, 19, 611-615.	2.9	75
884	Analysis of ovarian teratomas for isochromosome 12p: evidence supporting a dual histogenetic pathway for teratomatous elements. <i>Modern Pathology</i> , 2006, 19, 766-771.	2.9	73
885	Acquired cystic disease-associated renal tumors: an immunohistochemical and fluorescence in situ hybridization study. <i>Modern Pathology</i> , 2006, 19, 780-787.	2.9	92
886	Inverted papilloma of the urinary bladder: a molecular genetic appraisal. <i>Modern Pathology</i> , 2006, 19, 1289-1294.	2.9	59
887	Divergent pathway of intestinal metaplasia and cystitis glandularis of the urinary bladder. <i>Modern Pathology</i> , 2006, 19, 1395-1401.	2.9	83
888	Natural history of urothelial inverted papilloma. <i>Cancer</i> , 2006, 107, 2622-2627.	2.0	78
889	Interphase Fluorescence In situ Hybridization Analysis of Chromosome 12p Abnormalities Is Useful for Distinguishing Epidermoid Cysts of the Testis from Pure Mature Teratoma. <i>Clinical Cancer Research</i> , 2006, 12, 5668-5672.	3.2	67
890	Clonal Origin of Metastatic Testicular Teratomas. <i>Clinical Cancer Research</i> , 2006, 12, 5377-5383.	3.2	36
891	Molecular Evidence for Independent Origin of Multifocal Neuroendocrine Tumors of the Enteropancreatic Axis. <i>Cancer Research</i> , 2006, 66, 4936-4942.	0.4	50
892	Expression of EphA2 and Ephrin A-1 in Carcinoma of the Urinary Bladder. <i>Clinical Cancer Research</i> , 2006, 12, 353-360.	3.2	109
893	Molecular Evidence for the Same Clonal Origin of Multifocal Papillary Thyroid Carcinomas. <i>Clinical Cancer Research</i> , 2006, 12, 2414-2418.	3.2	87
894	Small-cell carcinoma of the urinary bladder: diagnosis and management. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1707-1713.	1.1	28
895	Prostate. , 2006, , 1219-1246.		0
896	Urinary Bladder. , 2006, , 1175-1218.		0
897	Tumors of the Kidney. , 2006, , 1147-1173.		0
898	Loss of Heterozygosity in Bone Marrows of Patients with Iron-Deficiency Anemia.. <i>Blood</i> , 2006, 108, 4863-4863.	0.6	0
899	23 Role of Immunohistochemical Expression of OCT4 in Ovarian Dysgerminoma. <i>Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas</i> , 2005, 4, 493-498.	0.0	0
900	Closest Distance Between Tumor and Resection Margin in Radical Prostatectomy Specimens. <i>American Journal of Surgical Pathology</i> , 2005, 29, 225-229.	2.1	63

#	ARTICLE	IF	CITATIONS
901	OCT4 Immunohistochemistry Is Superior to Placental Alkaline Phosphatase (PLAP) in the Diagnosis of Central Nervous System Germinoma. <i>American Journal of Surgical Pathology</i> , 2005, 29, 368-371.	2.1	112
902	Is it necessary to separate clinical stage T1c from T2 prostate adenocarcinoma?. <i>BJU International</i> , 2005, 96, 777-780.	1.3	28
903	Visual estimation of tumour extent is not an independent predictor of prostate specific antigen recurrence. <i>BJU International</i> , 2005, 96, 1253-1257.	1.3	13
904	Eosinophilic and classic chromophobe renal cell carcinomas have similar frequent losses of multiple chromosomes from among chromosomes 1, 2, 6, 10, and 17, and this pattern of genetic abnormality is not present in renal oncocytoma. <i>Modern Pathology</i> , 2005, 18, 161-169.	2.9	186
905	Preoperative prediction of Gleason grade in radical prostatectomy specimens: the influence of different Gleason grades from multiple positive biopsy sites. <i>Modern Pathology</i> , 2005, 18, 228-234.	2.9	60
906	c-kit Expression in small cell carcinoma of the urinary bladder: prognostic and therapeutic implications. <i>Modern Pathology</i> , 2005, 18, 320-323.	2.9	74
907	Maximum tumor diameter is an independent predictor of prostate-specific antigen recurrence in prostate cancer. <i>Modern Pathology</i> , 2005, 18, 886-890.	2.9	83
908	Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5â€%ml) in whole-mount prostatectomy specimens. <i>Modern Pathology</i> , 2005, 18, 1022-1026.	2.9	116
909	Expression of CD117 (c-kit) receptor in dysgerminoma of the ovary: diagnostic and therapeutic implications. <i>Modern Pathology</i> , 2005, 18, 1411-1416.	2.9	68
910	Analysis of loss of heterozygosity and X chromosome inactivation in spleens with myeloproliferative disorders and acute myeloid leukemia. <i>Modern Pathology</i> , 2005, 18, 1562-1568.	2.9	20
911	Clonal divergence and genetic heterogeneity in clear cell renal cell carcinomas with sarcomatoid transformation. <i>Cancer</i> , 2005, 104, 1195-1203.	2.0	112
912	Clonal origin of lymph node metastases in bladder carcinoma. <i>Cancer</i> , 2005, 104, 1901-1910.	2.0	44
913	Molecular Evidence Supporting Field Effect in Urothelial Carcinogenesis. <i>Clinical Cancer Research</i> , 2005, 11, 6512-6519.	3.2	160
914	Elevated Expression of Angiogenin in Prostate Cancer and Its Precursors. <i>Clinical Cancer Research</i> , 2005, 11, 8358-8363.	3.2	67
915	Molecular Genetic Evidence for the Independent Origin of Multifocal Papillary Tumors in Patients with Papillary Renal Cell Carcinomas. <i>Clinical Cancer Research</i> , 2005, 11, 7226-7233.	3.2	89
916	Application of Molecular Diagnostic Techniques to Renal Epithelial Neoplasms. <i>Clinics in Laboratory Medicine</i> , 2005, 25, 279-303.	0.7	40
917	PREOPERATIVE PREDICTION OF SMALL VOLUME CANCER (LESS THAN 0.5 ML) IN RADICAL PROSTATECTOMY SPECIMENS. <i>Journal of Urology</i> , 2005, 174, 898-902.	0.2	49
918	IMPACT OF THE NUMBER OF POSITIVE LYMPH NODES ON DISEASE-FREE SURVIVAL IN PATIENTS WITH PATHOLOGICAL STAGE B1 NONSEMINOMATOUS GERM CELL TUMOR. <i>Journal of Urology</i> , 2005, 174, 143-145.	0.2	23

#	ARTICLE	IF	CITATIONS
919	DOES THE HISTOLOGY OF NODAL METASTASIS PREDICT SYSTEMIC RELAPSE AFTER RETROPERITONEAL LYMPH NODE DISSECTION IN PATHOLOGICAL STAGE B1 GERM CELL TUMORS?. <i>Journal of Urology</i> , 2005, 174, 1287-1290.	0.2	14
920	The Combined Percentage of Gleason Patterns 4 and 5 Is the Best Predictor of Cancer Progression After Radical Prostatectomy. <i>Journal of Clinical Oncology</i> , 2005, 23, 2911-2917.	0.8	89
921	Thyroid transcription factor 1 expression in small cell carcinoma of the urinary bladder: an immunohistochemical profile of 44 cases. <i>Human Pathology</i> , 2005, 36, 718-723.	1.1	137
922	Molecular Genetic Evidence for a Common Clonal Origin of Urinary Bladder Small Cell Carcinoma and Coexisting Urothelial Carcinoma. <i>American Journal of Pathology</i> , 2005, 166, 1533-1539.	1.9	175
923	Bladder cancer: Epidemiology, staging and grading, and diagnosis. <i>Urology</i> , 2005, 66, 4-34.	0.5	825
924	LYMPHOVASCULAR INVASION IS AN INDEPENDENT PROGNOSTIC FACTOR IN PROSTATIC ADENOCARCINOMA. <i>Journal of Urology</i> , 2005, 174, 2181-2185.	0.2	102
925	P53 expression in small cell carcinoma of the urinary bladder: biological and prognostic implications. <i>Anticancer Research</i> , 2005, 25, 2001-4.	0.5	15
926	PC Cell-Derived Growth Factor Expression in Prostatic Intraepithelial Neoplasia and Prostatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 1333-1337.	3.2	75
927	Endometrial Glandular Dysplasia: A Putative Precursor Lesion of Uterine Papillary Serous Carcinoma. Part II: Molecular Features. <i>International Journal of Surgical Pathology</i> , 2004, 12, 319-331.	0.4	74
928	Loss of 14-3-3 σ in Prostate Cancer and Its Precursors. <i>Clinical Cancer Research</i> , 2004, 10, 3064-3068.	3.2	91
929	OCT4. <i>Clinical Cancer Research</i> , 2004, 10, 8544-8547.	3.2	151
930	Fluorescence in situ hybridization analysis of chromosome 12p in paraffin-embedded tissue is useful for establishing germ cell origin of metastatic tumors. <i>Modern Pathology</i> , 2004, 17, 1309-1313.	2.9	76
931	Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. <i>Cancer</i> , 2004, 100, 2362-2366.	2.0	271
932	Does pT2b prostate carcinoma exist? Critical appraisal of the 2002 TNM classification of prostate carcinoma. <i>Cancer</i> , 2004, 100, 2573-2576.	2.0	76
933	Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. <i>Cancer</i> , 2004, 101, 83-89.	2.0	176
934	Laser capture microdissection analysis reveals frequent allelic losses in papillary urothelial neoplasm of low malignant potential of the urinary bladder. <i>Cancer</i> , 2004, 101, 183-188.	2.0	76
935	Prostate needle biopsies. <i>Cancer</i> , 2004, 101, 527-532.	2.0	52
936	Small cell carcinoma of the urinary bladder. <i>Cancer</i> , 2004, 101, 957-962.	2.0	268

#	ARTICLE	IF	CITATIONS
937	Bladder neck invasion is an independent predictor of prostate-specific antigen recurrence. <i>Cancer</i> , 2004, 101, 1563-1568.	2.0	56
938	Establishing a germ cell origin for metastatic tumors using OCT4 immunohistochemistry. <i>Cancer</i> , 2004, 101, 2006-2010.	2.0	135
939	PERINEURAL INVASION IN RADICAL PROSTATECTOMY SPECIMENS: LACK OF PROGNOSTIC SIGNIFICANCE. <i>Journal of Urology</i> , 2004, 172, 2249-2251.	0.2	56
940	Prostatic Intraepithelial Neoplasia: An Update. <i>Clinical Prostate Cancer</i> , 2004, 3, 26-30.	2.1	15
941	Molecular Genetic Evidence for Different Clonal Origins of Epithelial and Stromal Components of Phyllodes Tumor of the Prostate. <i>American Journal of Pathology</i> , 2004, 165, 1395-1400.	1.9	58
942	Cystic Trophoblastic Tumor. <i>American Journal of Surgical Pathology</i> , 2004, 28, 1212-1216.	2.1	49
943	OCT4. <i>American Journal of Surgical Pathology</i> , 2004, 28, 1341-1346.	2.1	141
944	Expression of Alpha-Methylacyl-Coenzyme A Racemase in Nephrogenic Adenoma. <i>American Journal of Surgical Pathology</i> , 2004, 28, 1224-1229.	2.1	85
945	OCT4 Staining in Testicular Tumors. <i>American Journal of Surgical Pathology</i> , 2004, 28, 935-940.	2.1	282
946	Nephroblastoma Arising in a Germ Cell Tumor of Testicular Origin. <i>American Journal of Surgical Pathology</i> , 2004, 28, 687-692.	2.1	57
947	Allelic Loss of the Active X Chromosome During Bladder Carcinogenesis. <i>Archives of Pathology and Laboratory Medicine</i> , 2004, 128, 187-190.	1.2	34
948	Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model. <i>Anticancer Research</i> , 2004, 24, 2135-40.	0.5	27
949	Down-regulation of fragile histidine triad expression in prostate carcinoma. <i>Cancer</i> , 2003, 97, 1447-1452.	2.0	17
950	Anatomic distribution of periprostatic adipose tissue. <i>Cancer</i> , 2003, 97, 1639-1643.	2.0	53
951	Molecular genetic alterations in the laser-capture-microdissected stroma adjacent to bladder carcinoma. <i>Cancer</i> , 2003, 98, 1830-1836.	2.0	99
952	Metanephric Adenoma Lacks the Gains of Chromosomes 7 and 17 and Loss of Y That Are Typical of Papillary Renal Cell Carcinoma and Papillary Adenoma. <i>Modern Pathology</i> , 2003, 16, 1060-1063.	2.9	101
953	Gains of Chromosomes 7, 17, 12, 16, and 20 and Loss of Y Occur Early in the Evolution of Papillary Renal Cell Neoplasia: A Fluorescent In Situ Hybridization Study. <i>Modern Pathology</i> , 2003, 16, 1053-1059.	2.9	121
954	High-Level Expression of EphA2 Receptor Tyrosine Kinase in Prostatic Intraepithelial Neoplasia. <i>American Journal of Pathology</i> , 2003, 163, 2271-2276.	1.9	112

#	ARTICLE	IF	CITATIONS
955	Identical Allelic Losses in Mature Teratoma and Other Histologic Components of Malignant Mixed Germ Cell Tumors of the Testis. <i>American Journal of Pathology</i> , 2003, 163, 2477-2484.	1.9	78
956	Stage pT1 bladder carcinoma: diagnostic criteria, pitfalls and prognostic significance. <i>Pathology</i> , 2003, 35, 484-491.	0.3	59
957	Predicting Tumor Volume in Radical Prostatectomy Specimens From Patients With Prostate Cancer. <i>American Journal of Clinical Pathology</i> , 2003, 120, 386-391.	0.4	71
958	Predicting Tumor Volume in Radical Prostatectomy Specimens From Patients With Prostate Cancer. <i>American Journal of Clinical Pathology</i> , 2003, 120, 386-391.	0.4	21
959	Molecular Evidence Supporting the Neoplastic Nature of Some Epidermoid Cysts of the Testis. <i>Archives of Pathology and Laboratory Medicine</i> , 2003, 127, 858-860.	1.2	25
960	Stroma adjacent to metastatic mature teratoma after chemotherapy for testicular germ cell tumors is derived from the same progenitor cells as the teratoma. <i>Cancer Research</i> , 2003, 63, 6063-8.	0.4	41
961	Expression of Group IIA Secretory Phospholipase A2 Is Elevated in Prostatic Intraepithelial Neoplasia and Adenocarcinoma. <i>American Journal of Pathology</i> , 2002, 160, 667-671.	1.9	142
962	Neuroendocrine Expression in Node Positive Prostate Cancer: Correlation With Systemic Progression and Patient Survival. <i>Journal of Urology</i> , 2002, 168, 1204-1211.	0.2	85
963	Cyclo-oxygenase-2 expression in primary cancers of the lung and bladder compared to normal adjacent tissue. <i>Cancer Detection and Prevention</i> , 2002, 26, 238-244.	2.1	16
964	Precise microdissection of human bladder carcinomas reveals divergent tumor subclones in the same tumor. <i>Cancer</i> , 2002, 94, 104-110.	2.0	79
965	Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002, 440, 3-11.	1.4	102
966	Relative promoter strengths in four human prostate cancer cell lines evaluated by particle bombardment-mediated gene transfer. <i>Prostate</i> , 2002, 51, 286-292.	1.2	11
967	Fas-Fas ligand signaling pathway mediates an interleukin-12-induced rejection of a murine prostate tumor system. <i>Prostate</i> , 2002, 53, 69-76.	1.2	6
968	Molecular Genetic Evidence for Different Clonal Origin of Components of Human Renal Angiomyolipomas. <i>American Journal of Surgical Pathology</i> , 2001, 25, 1231-1236.	2.1	79
969	Risk of prostate carcinoma death in patients with lymph node metastasis. <i>Cancer</i> , 2001, 91, 66-73.	2.0	322
970	Predicting Cancer Progression in Patients with Penile Squamous Cell Carcinoma: The Importance of Depth of Invasion and Vascular Invasion. <i>Modern Pathology</i> , 2001, 14, 963-968.	2.9	67
971	Inflammatory Pseudotumor and Sarcoma of Urinary Bladder: Differential Diagnosis and Outcome in Thirty-Eight Spindle Cell Neoplasms. <i>Modern Pathology</i> , 2001, 14, 1043-1051.	2.9	123
972	Cytokeratin 7 and Cytokeratin 20 in Primary Urinary Bladder Carcinoma and Matched Lymph Node Metastasis. <i>Archives of Pathology and Laboratory Medicine</i> , 2001, 125, 921-923.	1.2	73

#	ARTICLE	IF	CITATIONS
973	Conserved Genetic Findings in Metastatic Bladder Cancer. Archives of Pathology and Laboratory Medicine, 2001, 125, 1197-1199.	1.2	27
974	Flat intraepithelial lesions of the urinary bladder. , 2000, 88, 625-631.		85
975	Inverted urothelial papilloma. , 2000, 88, 632-636.		45
976	Paraganglioma of the urinary bladder. , 2000, 88, 844-852.		105
977	Atypical nephrogenic metaplasia of the urinary tract. , 2000, 88, 853-861.		68
978	World Health Organization and International Society of Urological Pathology classification and Two-number grading system of bladder tumors. , 2000, 88, 1513-1516.		20
979	Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma. , 2000, 88, 1663-1670.		127
980	Squamous papilloma of the urinary tract is unrelated to condyloma acuminata. , 2000, 88, 1679-1686.		56
981	Predicting the survival of bladder carcinoma patients treated with radical cystectomy. , 2000, 88, 2326-2332.		135
982	Preoperative Prediction of Surgical Margin Status in Patients With Prostate Cancer Treated by Radical Prostatectomy. Journal of Clinical Oncology, 2000, 18, 2862-2868.	0.8	125
983	Extranodal Extension in Lymph Node-Positive Prostate Cancer. Modern Pathology, 2000, 13, 113-118.	2.9	56
984	Grading and Staging of Bladder Carcinoma in Transurethral Resection Specimens. American Journal of Clinical Pathology, 2000, 113, 275-279.	0.4	124
985	Predicting extravesical extension of bladder carcinoma: a novel method based on micrometer measurement of the depth of invasion in transurethral resection specimens. Urology, 2000, 55, 668-672.	0.5	26
986	CHARACTERIZATION AND PREDICTORS OF PROSTATE SPECIFIC ANTIGEN PROGRESSION RATES AFTER RADICAL RETROPUBIC PROSTATECTOMY. Journal of Urology, 2000, 164, 749-753.	0.2	31
987	Flat intraepithelial lesions of the urinary bladder. , 2000, 88, 625.		2
988	CHARACTERIZATION AND PREDICTORS OF PROSTATE SPECIFIC ANTIGEN PROGRESSION RATES AFTER RADICAL RETROPUBIC PROSTATECTOMY. Journal of Urology, 2000, 164, 749-753.	0.2	10
989	Predicting Cancer Progression in Patients With Stage T1 Bladder Carcinoma. Journal of Clinical Oncology, 1999, 17, 3182-3187.	0.8	128
990	Allelic imbalance in the clonal evolution of prostate carcinoma. Cancer, 1999, 85, 2017-2022.	2.0	52

#	ARTICLE	IF	CITATIONS
991	Overexpression of the wild type p73 gene in human bladder cancer. <i>Oncogene</i> , 1999, 18, 1629-1633.	2.6	124
992	p53 Protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy. <i>Cancer</i> , 1999, 85, 1293-1299.	2.0	57
993	Predictors of cancer progression in T1a prostate adenocarcinoma. , 1999, 85, 1300-1304.		36
994	Allelic imbalance in the clonal evolution of prostate carcinoma. , 1999, 85, 2017-2022.		28
995	p53 Alteration in regional lymph node metastases from prostate carcinoma. , 1999, 85, 2455-2459.		38
996	Survival of patients with carcinoma in situ of the urinary bladder. <i>Cancer</i> , 1999, 85, 2469-2474.	2.0	143
997	Tumor size predicts the survival of patients with pathologic stage t2 bladder carcinoma. , 1999, 85, 2638-2647.		84
998	Hemangioma of the urinary bladder. , 1999, 86, 498-504.		71
999	Neurofibroma of the urinary bladder. <i>Cancer</i> , 1999, 86, 505-513.	2.0	72
1000	Dedifferentiation in the metastatic progression of prostate carcinoma. , 1999, 86, 657-663.		54
1001	Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer. , 1999, 86, 1035-1043.		117
1002	Progression of T1 bladder tumors. , 1999, 86, 910-912.		14
1003	Correlation of margin status and extraprostatic extension with progression of prostate carcinoma. , 1999, 86, 1775-1782.		194
1004	Urothelial papilloma of the bladder. , 1999, 86, 2098-2101.		59
1005	Papillary urothelial neoplasms of low malignant potential. , 1999, 86, 2102-2108.		90
1006	Mutation and expression analysis of the p73 gene in prostate cancer. , 1999, 39, 94-100.		31
1007	TREATMENT CHANGES IN PROSTATIC HYPERPLASIA AND CANCER, INCLUDING ANDROGEN DEPRIVATION THERAPY AND RADIOTHERAPY. <i>Urologic Clinics of North America</i> , 1999, 26, 465-479.	0.8	23
1008	CYSTIC RENAL CELL CARCINOMA IS CURED BY RESECTION: A STUDY OF 24 CASES WITH LONG-TERM FOLLOWUP. <i>Journal of Urology</i> , 1999, 161, 408-411.	0.2	128

#	ARTICLE	IF	CITATIONS
1009	DIAGNOSIS AND GRADING OF BLADDER CANCER AND ASSOCIATED LESIONS. Urologic Clinics of North America, 1999, 26, 493-507.	0.8	82
1010	p53 Protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy. Cancer, 1999, 85, 1293-1299.	2.0	2
1011	Urothelial papilloma of the bladder. , 1999, 86, 2098.		2
1012	Papillary urothelial neoplasms of low malignant potential. Cancer, 1999, 86, 2102-2108.	2.0	14
1013	Natural History of Urothelial Dysplasia of the Bladder. American Journal of Surgical Pathology, 1999, 23, 443-447.	2.1	142
1014	Villous Adenoma of the Urinary Tract: A Report of 23 Cases, Including 8 With Coexistent Adenocarcinoma. American Journal of Surgical Pathology, 1999, 23, 764.	2.1	112
1015	Prevalence and Distribution of Prostatic Intraepithelial Neoplasia in Salvage Radical Prostatectomy Specimens After Radiation Therapy. American Journal of Surgical Pathology, 1999, 23, 803.	2.1	46
1016	Diagnosis of Prostate Cancer in Needle Biopsies After Radiation Therapy. American Journal of Surgical Pathology, 1999, 23, 1173.	2.1	81
1017	Independent origin of multiple foci of prostatic intraepithelial neoplasia. Cancer, 1998, 83, 1995-2002.	2.0	174
1018	Predictors of survival for prostate carcinoma patients treated with salvage radical prostatectomy after radiation therapy. Cancer, 1998, 83, 2164-2171.	2.0	72
1019	Evidence of Independent Origin of Multiple Tumors From Patients With Prostate Cancer. Journal of the National Cancer Institute, 1998, 90, 233-237.	3.0	191
1020	Long-Term Follow-up of Untreated Stage T1a Prostate Cancer. Journal of the National Cancer Institute, 1998, 90, 1105-1107.	3.0	13
1021	Cancer Volume of Lymph Node Metastasis Predicts Progression in Prostate Cancer. American Journal of Surgical Pathology, 1998, 22, 1491-1500.	2.1	118
1022	CWR22 Xenograft as an Ex Vivo Human Tumor Model for Prostate Cancer Gene Therapy. Journal of the National Cancer Institute, 1996, 88, 607-611.	3.0	26
1023	Gene Transfer via Particle Bombardment: Applications of the Accell Gene Gun. , 1994, , 193-209.		9
1024	Particle Bombardment-Mediated Gene Transfer and Expression in Rat Brain Tissues. Nature Biotechnology, 1993, 11, 497-502.	9.4	81
1025	The Seminal Vesicles and Ejaculatory Ducts. , 0, , 169-178.		1
1026	Basic Anatomy and Histology of the Prostate. , 0, , 1-9.		0

#	ARTICLE	IF	CITATIONS
1027	Inflammatory and Tumor-like Conditions of the Prostate. , 0, , 10-28.		0
1028	Preneoplastic Lesions and Conditions of the Prostate. , 0, , 29-45.		0
1029	Adenocarcinoma of the Prostate. , 0, , 46-59.		0
1030	Gleason Grading of Prostate Cancer. , 0, , 60-76.		0
1031	Histologic Subtypes of Prostatic Carcinoma. , 0, , 77-93.		0
1032	Neuroendocrine Tumors of the Prostate. , 0, , 94-100.		0
1033	Pathologic Prognostic Factors of Prostate Cancer. , 0, , 101-113.		0
1034	Pathology of the Prostate after Treatment. , 0, , 114-126.		0
1035	Basic Molecular Pathology of Prostate Cancer. , 0, , 127-133.		0
1036	Rare Forms of Prostatic Carcinomas. , 0, , 134-140.		0
1037	Tumors and Tumor-like Conditions of the Prostate Stroma. , 0, , 141-148.		0
1038	Soft Tissue and Miscellaneous Primary Tumors of the Prostate. , 0, , 149-156.		0
1039	Metastatic and Secondary Tumors of the Prostate. , 0, , 157-168.		0
1040	Pathology of the Prostatic Urethra. , 0, , 179-192.		0
1041	Practical Immunohistochemistry of Prostate Cancer and Related Lesions. , 0, , 193-208.		1